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'The credit belongs to the man who is actually 
in the arena whose face is marred by dust and 
sweat and blood; who at best knows in the end 
the triumph of high achievements and who at 
worst if he fails at least fails while daring 
greatly so that his place shall never be with 
those cold and timid sou1s who know neither 
victory not defeat. 1 
Franklin T Roosevelt 
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CHAPTER I 
INTRODUCTION 
The modern practice of medicine has an ever-increasing dependency on the 
blood bank industry. Indeed, on many occasions there is an unwarranted and 
inappropriate use of hemotherapy. 
The first recorded blood transfusion was given to Pope Innocent VIII in 1492 
(Narengo-Rowe, 1982). 
three blood donors 
This treatment was unsuccessful, and the patient and all 
died as a result of the experiment. Since then physicians 
have been mesmerized by the 1 0mnipotent 1 powers of extraneous blood in reversing 
disease processes, regardless of the inherent complications or the logical 
indications for such blood transfusions. 
It has been estimated that 12 million units of blood are transfused yearly 
into patients in the United States. This blood comes primarily from volunteer 
sources, but paid donors must necessarily be used, in order to make up for 
shortages created by the ever increasing demand. In addition, the cost of whole 
blood has risen steadily to $100.00 per unit in some hospitals and frozen blood 
is double this price. On average 2.5 units of blood are used for each trans-
fusion and retrospective data analyses of the need for individual blood trans-
fusions have unifonnly demonstrated that at least half of all blood transfusions 
were unnecessary. 
The risks of using homologous blood include isosensitization~ disseminated 
intravascular coagulopathy, febrile reactions, bacterial contamimation, thrombo-
phlebitis, hepatitis, cytomegalic viruses infection, syphilis~ herpes, malaria, 
trypanosomiasis, thrombocytopenia, and reduced factor-VIII mediated coagulopathy. 
Cardiac arrhythmias may occur as a result of vascular overload and hemosiderosis. 
Blood, mismatched as a result of technical errors has also sometimes 
contributed to catastrophies. The risk of hepatitis is 20-46% with paid donors, 
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and ranges from 10-15% when volunteers are used for the provision of donor blood. 
Since only one-third of the patients become clinically jaundiced, it is difficult 
to detennine the total incidence without performing liver enzymes tests and 
antigen screening studies in all cases. The exact number of deaths directly 
related to the transfusion of blood is also difficult to determine due to various 
factors (including the failure of many hospitals to report such occurrences). Of 
the deaths which have been attributed to blood transfusion, 60% '"ere related to 
mismatched blood and 30% resulted from serum hepatitis (Myhre, 1980). 
A number of methods can be employed in order to avoid the use of blood 
transfusions. For additional information the reader is referred to Fig. 1 in 
which the subject is dealt with schematically. 
Surgical techniques may be improved, in order to avoid blood loss, by 
employing hypotension, hypothermia, autotransfusion, intravenous iron therapy, 
Folic Acid, and intravenous hyperalimentation to increase the rate of natural 
hemoglobin production. Reassessment of the concept of the 1 need' for a 
hemoglobin of 10 gm%, exploring the full potential of perfluorochemicals, and the 
use of erythopoietin will greatly reduce the costs, risks, and shortages which 
are associated with autologous blood transfusions. 
Grant (1921) reported the first peroperative autologous blood transfusion. 
Milles (1963) documented a similar procedure and Cowell (1974) presented a report 
on a series of pediatric orthopaedic patients who were treated using this method 
of autologous transfusion. The safety of preoperative blood collection for 
subsequent retransfusion into patients with coronary insufficiency was 
demonstrated by Cove (1976) and Ebert (1941) showed that plasma volume will 
increase over 72 hours to compensate for the loss of red blood cells. Finch 
(1950) showed that the limiting factor to effective hematopoesis after blood loss 
is the depletion of iron-stores. Total dose infusion of intravenous Iron was 
shown to replace these stores quite rapidly. 
Mallory (1976) and Eckhardt (1978) reported two series of patients undergoing 
hip replacement utilizing preoperative blood harvesting. The average blood 
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donation was 2.6 units per patient. Mallory stored liquid blood for only 8 days 
before retransfusion~ while Eckhardt used 4 day intervals between donation and 
infusion. Blood in the former study was cit rated and stored at 4 'c. Frozen red 
cells were drawn at 6 day intervals and stored with glyceryl at -87'. Fifty-five 
percent of the patients in both groups required no additional blood following 
surgery. This method does 
techniques, though the cost 
not require sophisticated handling or new anesthetic 
involved in freezing red blood cells is not 
insignificant. Some reports have shown a decrease in the rate of hepatitis 
transmission in patients receiving homologous and autologous frozen blood. 
When blood loss during surgical procedures is estimated preoperatively to be 
greater than 500 CC 1 S} acute isovolemic hemodilution may be performed in those 
patients not suffering from coronary artery disease or congestive heart failure. 
This technique was originally planned to be used to conform with the religious 
objections of Jehovah's Witnesses. These patients will not accept any type of 
blood storage or homologous blood transfusion. Witnesses will also not accept 
this technique of hemodi 1 uti on if blood is removed from their own ci rcul ati on 
and storage 
hemodilution 
takes place 
can conserve 
before reinfusion. This technique of isovolemic 
2-3 units of whole blood. It is accomplished by 
removing as much as 50% of the patient 1s red blood cells prior to actual surgery, 
and then replacing the volume by using crystalloid solutions in a ratio of 3:1. 
This type of dilution will reduce the patient's hematocrit under control 
conditions, thus minimizing the operative red cell loss by nearly 50%. 
The first intraoperative autotransfusion was reported by Blundell (1818) and 
the technique was later employed in intracranial surgery by Cushing (1925). 
Carbon monoxide intoxication has been treated by Highmore (1874) using these 
methods. The practical application of intraoperative hemodilution was shown by 
Laks (1974). In a series of total hip replacement patients, he demonstrated the 
compensatory ability of the body to overcome decreased tissue oxygenation through 
increased cardiac output. No changes were reported in the 1 actate-pyruvate 
ratio~ muscle surface pH or the patient 1 S arteriovenous oxygen difference. 
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Retransfusion of the patient's own blood reduces the hazard of serum 
hepatitis, as well as the risk of mismatched blood (all of which can occur with 
homologous 
autologous 
patient. 
transfusions). 
blood storage, 
With further modification, such as the elimination of 
this technique is accepted by the Jehovah's Witness 
Using the 1 Cell-saver 1 apparatus (manufactured by the Haemonetics 
Corporation), Flynn (1981) reported 55% harvesting of the red blood cells which 
would have normally been 'lost' during surgery. He studied 125 patients 
undergoing orthopaedic procedures (mainly spinal fusions). Turner (1968) also 
salvaged as much as 61% of the red blood cells in his series. Bonnett et al. 
(1981) reported similar results. 
The cell salvage rate can be increased to as much as 90% by keeping the 
tissues moist, wringing-out sponges, and the meticu1ous use of the suction 
apparatus. When continuous blood loss occurs in the recovery room (or in the 
intensive care unit) from surgical drains, the cell-saver can be used in the 
continuing effort to recover RBC' s. \~e have had no camp 1 i cations from this 
technique. The new computerized-model cell-saver can easily be operated by the 
anesthesiologist, thus eliminating the need for a technician and thereby reducing 
the cost. 
Hypotension may be employed to reduce intraoperative blood loss and was first 
reported by Gardner (1946), using artet·iotomy and subsequent reinfusion. 
Hypotension may also be induced by high spinal anesthesia and ganglionic blocks. 
Anesthesia employing induced hypotension can be regarded as a method in which 
a significant portion of the circu-lating blood volume is pooled, only to be 
reintroduced to become a significant part of the effective circulatory volume at 
a 1 ater date. Comp 1 i cations of this procedure (as reported by Little I 1955) 
include cerebrovascular accidents and a no xi a. There were 113 deaths in 12,264 
patients treated with hypotensive anesthesia. By excluding patients with renal 
disease, and also those patients on antihypertensive medications, Charnley (1974) 
showed that hypotensive anesthesia decreased blood loss during surgery, decreased 
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operative time and reduces the number of blood transfusions needed. 
By maintaining intraoperative systolic blood pressures between 60 and 75 mm 
Hg, Davis et al. (1979) reported a reduction of blood replacement by 45% during 
hip surgery; his patients received Halothane and Pentolinium anesthesia. ~1allory 
(1976) reported a 50% decrease in post-operative homologous transfusions, and 25% 
reduction in total operative time. Thompson et al. (1978), in a series of 
patients undergoing hip surgery, d~nonstrated a 55% decrease in estimated blood 
loss with Halothane-induced hypotension, and a 65% reduction when hypotension was 
obtained using nitroprusside. All three investigators saw no increase in the 
i nci de nee of postoperative hemorrhage, and no hepatic, renal, or myocardial 
complications were observed. We have obtained similar results with our patients. 
A skilled and informed anesthesiologist can easily apply these hypotensive 
techniques and can also induce hypothermia in order to reduce intraoperative 
blood loss. 
Little, if any, attention has been paid to the improvement of surgical 
techniques and the refinement of surgical instruments in the medical literature 
in recent years. The electrocautery and the carbon dioxide laser device have 
dramatically reduced blood loss without compromising wound healing. 
In the present series of 5000 Jehovah's Witness patients, the incidence of 
wound infections, 
no different to 
surgery. In this 
comparable series~ 
delayed wound healing, wound dehiscence or 1 burst abdomen 1 was 
the incidence reported in patients who underwent conventional 
series blood loss was reduced to 70% of that occurring in a 
The craftsmanship of the surgeon, and the refinement of his instruments, is 
as important in reducing blood loss as any other factor. The blind reliance on 
the blood bank to compensate for the 1 oss of blood resulting from technical 
laxity during surgery must be changed. 
Several years ago, the idea that some man-made fluid could take over the 
oxygen-carrying capacity of human blood was a dream. Now it is a reality with 
Fluosol-DA 20%. This milky-white fluid is the by-product of the petroleum 
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industry. It is closely related to Teflon and holds the promise of making 
important contributions in patient therapy and research. 
Fluosol-DA 20% belongs to a family of synthetic organic chemicals (called 
perfluorocarbons) in which oxygen solubility is very high. They were developed 
during World War II as an off-shoot of the 'Manhatten Project'. Fluosol-DA 20% 
is an emulsion of perfluorodecalin and perfluorotripropelennamine, as well as 
hydroxyethyl starch. It contains a mixture of electrolytes to maintain osmotic 
pressure, and contains no clotting or immunological factor. 
To date, Fluosol emulsion has been injected into 490 patients in Japan 
without any serious side-effects. Fluosol has a life span in the circulation of 
only 72 hours. It is, however, being constantly improved by the researchers of 
the Green Cross Corporation under the direction of Doctor Naito. It is hoped 
that the new generations of perfluorocarbons (called Fluosol-DA 35-2) will not 
have to be stored in a frozen state (as is necessary for Fluosol-DA 20%), and can 
be used effectively in patients without the need for the high tension oxygen 
mask. The present generation of perfluorocarbons have proved themselves to be 
relatively atoxic in animal experimentation, though a certain amount of 
culmulation is seen in the reticuloendothelial system. In clinical work, this 
has not limited their usefulness, and potential allergic reactions have been 
avoided by the concomitant use of corticosteroids. 
The potential capabilities of such oxygen-carrying fluids are only limited by 
man's own imagination. Their advantages are long-shelf life, no hepatitis, the 
elimination of typing and cross-matching blood, and Fluosol 's relative low cost. 
It can be used in the Third World countries where modern blood banks are still in 
thei r i nf ancy. 
In the United States, we have the largest series of patients to date who have 
received Fluosol-DA 20%. This amounts to 17 patients at the moment. We are 
gratified and impressed by the ability of this product to carry oxygen in those 
patients who refuse blood transfusions. These Jehovah's Witness patients, some 
of whom had very low haemoglobin concentrations, received an average dose of 20 
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ml/kg, and were then able to undergo emergency surgery. There were no 
intraoperative mortalities and in the most anemic patient Fluosol carried as much 
as 45% of the consumed oxygen. 
Fluosol-DA 20% is an oxygen-carrying fluid which can be extremely helpful 
when blood is unavailable, or when it cannot be used for various reasons. It has 
never, however, been the intention that it should completely replace the 
necessity for the use of blood. It is not metabolized, but rather 'picked up' by 
the reticuloendothelial system. It is transported to the liver and excreted 
through the lungs and the skin. We have not encountered any serious 
complications from its use. 
Recent interest in the availability of erythropoietin (which increases the 
rate of hemoglobin production in clinical situations) has offered another 
interesting new avenue for decreasing reliance on the blood bank. Perhaps when 
new data on the use of this substance becomes available, it can be combined with 
the already-existing methods of reducing blood use. 
It is our hope that by combining the features, techniques and the ideas 
described above, our dependency on the blood bank will be reduced. We will 
describe all of these techniques in detail in this manuscript. Attempts will be 
made to demonstrate that the best way to avoid transfusions is to exercise great 
care in the operating room and that, if transfusions are needed, the best blood 
one can give a patient is his own. 
Proposed Plan for the Reduction of Homologous Transfusion 
j 
Techniques to Reduce Blood Loss 
1 
1. Refined surgical approach 
2. Reduce operative blood loss 
3. Modify surgical procedures and 
strategy 
4. Adopt different anesthetic 
techniques 
5. Instrumentation 
a. cautery 
b. 1 aser 
6. Hypotension 
7. Autotransfusion 
8. Hypothenni a 
\ 
Blood Substitutes 
l 
1. Perfluorocarbons 
2. Volume replacement 
a. 0 ext.ran 
b. Gelatine 
c. Starch solution 
3. Bone marrow stimulation 
a. Imferon 
b. Folic acid 
c. Anabolic steroids 
Fig 1: A schematic overview of a number of methods that can be employed 
in order to avoid the use of blood transfusions. 
First the Nazis went after the Jews but I was not a Jew 
so I did not object. Then they went after the Catholics 
but I was not a Catholic so I did not object. Then they 
went after the Trade-Unionists but I was not a Trade-
Unionist so I did not object. They came after me and 
there was no one left to object. 
Martin Niemoller, 
German Theologian. 
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CHAPTER II 
SURGERY WITHOUT BLOOD TRANSFUSION 
II- The Performance Of Major Surgery In Jehovah's Witnesses. 
General Considerations 
The performance of major surgery in Jehovah's Witnesses presents the majority 
of physicians with a moral and ethical dilemma. This is because most doctors see 
only an occasional member of this religious group during a lifetime of practice. 
The few physicians who treat these patients on a regular basis are confronted 
with a great challenge but, at the same time, achieve a great sense of satisfac-
tion after successful completion of therapy. 
Since we believe that most physicians are not well acquainted with the moral~ 
legal, and ethical issues involved in the surgical treatment of Jehovah's >litness 
patients, we present the following combined series, which, to the best of our 
knowledge, is the largest ever reported in either the U.S.A., or the world litera-
ture. It is our hope that this article will not be viewed as a mere collection 
of numbers and statistics, but rather as a testimony to the fact that major 
surgery can be carried out successfully on patients who~ because of strong 
religious convictions, refuse to accept transfusions of blood, or blood products. 
Clinical Material and Results 
From 1973 to 1982, 4,632 patients ranging in age from 1 month to 96 years 
underwent major surgery without the use of blood or blood products. Twenty two 
patients died within 4 weeks following surgery from a variety of reasons. This 
represents a postoperative mortality of 0,48%. Wound infection rate was 5,9%, 
Table I: Estimated Blood Loss and Operative Time in ~1ajor Surgery - From 1980-1982 
Procedure No. of Cases 
Cholecystomy 115 
Common Duct Expr. 11 
Gastrectomy sub total 23 
Gastrectomy total 5 
Vagotomy & pyloroplasty 33 
Total abdominal hysterectomy 85 
Right Colectomy 19 
Left Colectomy 21 
Total Colectomy 8 
Splenectomy (elective) i7 
Splenectomy (emergency) 6 
Gastroesophageal antiflux 16 
Nephrectomy 29 
Total esophagectomy 7 
E sophegogas trectomy 9 
Abdominal pereniel resection 67 
Abdominal aneurysm resection 
(elective) 9 
Modified Radical ~lastectomy 45 
pneumonectomy 4 
Lobectomy (lung) 14 
Coronary bypass ( 1-4 vessels) 109 
Blood loss in cc 
55 
70 
105 
140 
60 
70 
90 
130 
160 
40 
350 
75 
190 
375 
230 
140 
275 
130 
200 
250 
675 
Average Operation Time 
in minutes 
20 
40 
45 
65 
30 
25 
45 
40 
85 
28 
40 
45 
60 
90 
(2 team approach) 
70 
63 
80 
60 
75 
80 
100 
~ 
0 
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and postoperative incisional hernia rate was 3,7%. Four cases of total disruption 
of the abdominal wall occurred. One patient died from frank hemorrhage. There 
were two cases of disseminated intravascular coagulation. 
These patients were operated upon in two small community hospitals with a 
total capacity of approximately 300 beds. Three thousand nine hundred and fifty 
were classfied as general and gynecological. while the remainder were operated 
upon by 
thoracic 
specialists 
surgery. The 
in orthopaedics, urology, neurosurgery, cardiovascular or 
overall average blood loss was 140 cc per case. The types 
of procedures performed were as follows: 
Genera 1 surgery: Esophagectomy, gastrectomy, cholecystectomy, common duct 
exploration, biliary diversion procedures, hepatic lobectomy, small and large 
bowel resection, combined abdominoperineal resection, portosystemi c shunts, 
splenectomy, exploration of abdominal trauma) mastectomy with and without 
reconstruction, thyroidectomy, 
aneurysmectomy both elective 
operations, amputation of the 
herniorrhaphy, anti reflux procedures, abdominal 
and emergency, peripheral vascular bypass 
extremities, abdominal wa1l reconstruction, and 
reduction and augmentation mammoplasty. The numbers of the different operations 
together with the est;mated blood loss is shown in Table I. 
Gynecology: Total abdominal hysterectomy, bilateral 
cesarean section, vaginal hysterectomy, anterior and 
uterine suspension procedures. 
salpingo-oophorectomy, 
posterior repair, and 
Thoracic: Lobectomy, pneumonectomy, pacemaker insertion (either transvernous 
or transthoracic), peri cardectomy, transthoracic repair of hiatus hernia, and 
esophagectomy. 
Neurosurgery: Excision of meningioma and glioma. 
Cardiovascular: Coronary artery bypass, repair of ventri cul osepta1 defect, 
repair of atri oseptal defect, mitral and aortic valve replacement. 
Orthopaedics: Total hip replacement, total knee replacement, cervical fusion, 
lumbar disc surgery, Harrington rod insertion and spinal fusion for scoliosis, 
open reduction and internal fixation of fractures in both upper and lower 
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extremities, and pinning of hip fractures. In total 331 procedures were carried 
out. 
Urological: Partial or total nephrectomy, anti reflux procedures, 
nephrolithotomy, ureterolithotomy, pyelolithotomy, transurethral resection of the 
p restate, open prostatectomy, repair of hypospadias, or Marshall-Marchetti 
procedure and cystectomy. 
Expeditious preoperative workup, prompt surgical intervention in all cases of 
haemhorrage, meticulous surgical technique, and good surgical a_ssistance were 
stressed in every case. Blood was not typed or crossmatched, either before or 
after 
fonn, 
surgery. 
as well 
Prior to surgery each patient signed an informed surgical consent 
as a fonn releasing the hospital and the physician from 
responsibility for untoward complications arising from tl1e patient 1 S refusal to 
accept blood or its derivatives. 
Intraoperative autotransfusion, hypotensive and hypothermic anesthesia was 
cases. Crystalloid solutions, dextran, and used in 1 ess than 5% of the 
hydroxyethyl starch were 
dextran), folic acid~ 
administered liberally 
used 
B-12, 
both 
reduction in blood loss can 
for volume replacement. Intravenous Imferon {iron 
and Deca-Durabol in ( nendral one decanoate) were 
peroperatively and postoperatvely. The great 
be primarily attributed to the extensive use of 
electrocautery in these patients. 
Emergency and elective procedures were performed on patients whose hemoglobin 
levels ranged from 1.6 gm% to 18.0 gm%. One hundred and five patients were 
operated upon with a preoperative hemoglobin concentration below 5.0 gms% and 
there was no subsequent mortality in these cases. With 92% follow-up, only 1 
death was attributed directly to exsanguination, and only 1 patient had to be 
returned to the Operating Room for hemostatic control following his initial 
surgery. 
Fluosol-DA 20% was administered to 9 patients, in 6 of whom successful 
operations were subsequently carried out. 
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Discussion 
The Jehovah's Witness organization was founded in 1881 by Charles Taze Russell 
in Pittsburgh, Pa. From 1879 until 1930 the group was called the Watchtower and 
Bible Tract Society. In 1951, under the leadership of Judge Rutherford of 
Missouri, the society adopted the name of Jehovah 1 S Witnesses. The society is 
extremely prolific, publishing two bimonthly magazines entitled The Watchtower 
and Awake. These journals are published in 82 languages. 
Most, if not all, of their confrontations with the medical profession have 
been over their steadfast refusal to accept transfusions of blood or blood 
products. The reference most frequently quoted by them to substantiate their 
beliefs is as follows: 'For it is the life of all flesh, the blood of it is for 
the life thereof. Therefore I said unto the children of Israel, ye shall eat the 
blood of no manner of flesh for the life of the flesh is the blood thereof. 
Whoever eateth it shall be cut off' (Leviticus). 
Jehovah's Witnesses recognise no difference between the eating of blood and 
the receiving of it intravenously; thus they vehemently resist transfusions. In 
their widely quoted publication, 'Blood, Medicine and The Law of God', 
1 Jehovah's Witnesses 1 and the 'Question of Blood', they clearly and succinctly 
make their fundamental beliefs known. They reject not only whole blood but also 
blood products such as albumin and plasma. They will allow the administration of 
any blood substitutes such as: glucose, dextran, saline, lactated Ringer 1 s etc. 
In addition, the society does not approve the use of an individal 1 S own stored or 
frozen blood. Thus, the surgeon's attempt to draw two units of blood prior to 
surgery, for the purpose of storage and 1 ater transfusion, wi 11 usually be 
rejected by the patient. 
Surgical thinking has never been unanimous on the subject of blood trans-
fusions. Not only do many now accept that surgery is possible without blood 
transfusions, but also leaders in many surgical fields are recognizing definite 
advantages in transfusi onl ess surgery. Cooley (1971) stated: 'We believe that 
our experience demonstrates the feasibility of open heart surgery in Jehovah 1 S 
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Witnesses, and moreover, indicates that blood transfusions can, and should be 
used sparingly to reduce the morbidity and mortality in all patients'. 
Roen and Velcek (1972) reported on their observations in urological surgery: 
10ur experience with Jehovah 1S Witnesses requiring operative procedures has 
demonstrated to us that blood transfusions are not necessarily' essential even 
when the hemoglobin levels are as low as 5.0 gm%, as in one of our cases. The 
only requirement is a careful and more meticulous operative technique~. 
Jehovah's Witnesses believe that physicians should not be expected to perform 
operations under conditions that they themselves sincerely believe would spell 
failure. They do not ask the impossible, but evidence is conclusive that they 
have not always had the benefit of the 'possible'. Some have mistakenly inter-
preted this stand of Jehovah 1s Witnesses as one in which an individual is exer-
cising his right to die. There is no such suicidal fanatisism in the thinking of 
the Jehovah's Witnesses. The very opposite is true; they are detenllined to 
exercise every precaution, at whatever cost, in order to obey what they consider 
God's law in all matters and thereby be assured of life, if not now, then in the 
future. In patients whom we have treated, we have carefully adhered to the 
requirements listed in Table II in order to perform surgery and our experience 
indicates that Jehovah 1 s Witnesses are extremely cooperative and pleasant to work 
with and that they follow instructions well, as long as they are certain that 
their religious beliefs will not be compromised. 
As far as is known, no Jehovah 1 s Witness has ever filed a lawsuit against an 
American physician for failing to administer blood. On the contrary, these 
patients have consistently attempted to resolve any grievances that they might 
have with the medical profession through their own judicial committee. He firmly 
believe that a patient, regardless of his religious beliefs, should be entitled 
to make what he considers the proper decision concerning his medical treatment 
and that the physician who chooses to treat such a patient is morally bound to 
adhere to such guidelines regardless of the circumstances. 
Understandably, caring for Jehovah's ~~itnesses might seem to pose a dilemma 
TABLE II: Considerations for successfully performing surgery in 
Jehovah 1 S Witness Patients. 
Absolute respect for the patient 1 S religious rules 
Evaluation for the chances of success 
a. Previous experience 
b. Published successes of others 
Blood release form signed by both husband and wife 
Informed surgical consent 
Coagulation screening 
Meticulous patient work-up 
Competent surgical assistance 
Sound surgical planning 
Meticulous intra-operative hemostasis 
Availability of autotransfusion devices 
Availability of Fluosol-DA 20% 
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for the physician dedicated to preserving life and health by employing all the 
techniques at his disposal. Editorially prefacing a series of articles about 
major surgery on Witnesses, Harvey (1980) admitted 'I do find annoying those 
beliefs that may interfere with my work 1 • But, he added: 1 Perhaps we too easily 
forget that surgery is a craft dependent upon the personal technique of 
individuals. Technique can be improved 1 • 
Bolooki (1981) took note of a disturbing report that one of the busiest 
trauma hospitals in Dade County, Florida, had a 'blanket policy of refusing to 
treat 1 Witnesses. He pointed out that 1 ffiOSt surgical procedures in this group of 
patients are associated with less risk than usual'. He added: 'Although the 
surgeons may feel that they are deprived of an instrument of modern medicine 
am convinced that by operating on these patients they will learn a great deal'. 
Rather than consider the Witness patient a problem, more and more physicians 
accept the situation as a medical challenge. In meeting the challenge they have 
developed a standard of practice for this group of patients that is accepted at 
numerous medical centers around the country. These physicians are, at the same 
time, providing care that is best for the patient 1 S total care. As Gardner et 
al. (1946) observed: 'Who would benefit if the patient's corporal malady is cured 
but the spiritual life with God) as he sees it, is compromized, which leads to a 
1 ife that is me ani ngl ess and perhaps WOI'Se than death itself'. 
Witnesses recognize that, medically, their firmly held conviction appears to 
add a degree of risk and may complicate their care. Accardi ngly, they generally 
manifest unusual appreciation for the care they receive. In addition to having 
the vital elements of deep faith and an intense will to live, they gladly 
cooperate with physicians and medical staff. Thus, both patient and physician 
are united in facing this unique challenge. 
The trend in medicine appears to be toward treating the 1 Whole man 1 • With 
regard to Jehovah 1 S Witnesses, this involves recognizing that their welfare would 
not be served by violating their fundamental religious convictions concerning 
blood. 
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Since the bulk of the authors experience has been with adult patients, it is 
difficult to comment on surgery in children, tor whom special consideration must 
obviously be given. However, when faced with surgical procedures in children, 
where extensive blood loss was anticipated, it was either recommended that 
surgery should not be perfonned at that point, or these chi 1 dren >~ere referred to 
centers where sympathetic physicians were willing to accept such cases. 
The majority of articles regarding the treatment of Jehovah's Witnesses with-
out blood transfusion have dealt with cardiovascular surgery. We hope that 
surgeons who have experience in other specialties and who have been treating 
Jehovah 1 S Witnesses for some time will publish results of their work in this most 
controversial area. 
We would argee with the statement by Kelly (1967) that 'No doctor can be 
positive that a person will die if he does not get a transfusion or live if he 
does. It is perhaps better that the odd person die, rather than that the funda-
mental right of refusing medical treatment be impaired. Patients have tile right 
to accept or reject a doctors advice according to their desires .... 1 
The avai 1 ability of Fl uoso 1-DA 20% which possesses the capabi 1 i ty of carrying 
oxygen has been very encouraging and has made treatment possible in a highly 
selected group of cases. We hope that when the efficacy of this material is 
finally proven, much of the resistance against the treatment of Jehovah's Witness 
patients on the part of the medical profession will subside. 
Finally, we wholeheartedly agree with Dunphy (1978) who has said: 
'Transfusion certainly makes the surgeon feel better. Perhaps we all have the 
tendency to transfuse to make ourselves more comfortable ... 1 When treating a 
Jehovah 1 S Witness patient, we will do well to consider his point of view. 
18 
Jl-i i The Surgical Approach to the Jehovah's Witness Patient B 1 eedi ng from 
Oesophageal Varices. 
The successful surgical management of bleeding esophageal varices in the 
cirrhotic patient remains, as always, a great dilemma. The questions of when to 
operate, on whom, what procedure to use or if to operate at all, remains, as they 
have been in the past, mostly unanswered. These problems become greatly 
magnified in scope and complexity when the patient in question is also a 
Jehovah's Witness who steadfastly refuses to accept blood or blood products even 
at the risk of dying. 
Realizing that the best operation for a particular patient is not necessarily 
the best operation possible, we will attempt in this paper to describe our 
experience with five cirrhotic Jehovah's Witness patients presenting with 
bleeding esophageal varices. 
Materials and Methods: 
Five Jehovah 1 S Witness patients, one male and four females, were treated for 
active gastrointestinal bleeding which was endoscopically diagnosed as being from 
esophageal varices. Two patients had previous duodenal ulcer disease and one had 
ulcerative colitis for which she had a total colectomy and ileostomy performed in 
the past. One patient had documented Laennec 1 s cirrhosis during a prior 
operation when a liver biopsy was performed at the time that a mesocaval shunt 
was attempted but had to be aborted because of technical complications. The 
other four patients had post-necrotic cirrhosis; two patients were classified as 
Class A, two as Class B and one as Class Con the Child Scale of Classifications. 
One patient had thrombocytopenia purpura. The surgical indications for these 
patients were anemia secondary to poorly controlled variceal bleeding by medical 
means. 
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Fig 2: Showing the EEA stapler in position prior to fixation 
20 
Operative T echni gues 
After adequate fluid resuscitation the patients were taken to surgery and 
given general 
with Ketami ne 
( F orane) and 
endotracheal anesthesia. Induction of anesthesia was accomp1iched 
and Ativan (Lorazepam) and the patients were carried on Fluothane 
Pavulon (Pancurodium Bromide). The patients were kept well 
oxygenated and as light as possible. The abdomen was entered through a generous 
upper midline incision. Liberal use of the electrocautery was employed in 
performing the operation and meticulous hanostasis was established throughout the 
procedure. The left lobe of the liver was retracted medially whenever possible. 
Prior to mobilization of the distal esophagus, a large Maloney esophageal dilator 
was passed by the anesthesiologist and guided into the gastroesophageal junction. 
The coronary vein and the large periesophageal veins were ligated with #00 silk 
surture material. The distal end of the esophagus has been mobilized under 
vision and held up with the aid of a Penrose drain. A generous gastrotomy 
incision was then performed using the cautery on the greater curvature using stay 
sutures in order to keep the edges apart. A 28 mm EEA stapler instrument was 
then inserted into the 
gether. The instrument 
stomach 
guided 
with 
under 
the cartridge and anvil approximated to-
vision through the gastro-oesophageal 
junction as the dilator is slowly withdrawn. The anvil and cartridge then 
separated, and a #0 silk ligature is passed around the oesphagus approximately 2 
em from the gastroesophgeal junction and tied securely and snugly around the 
shaft of the open instrument (Fig 2). The anvil and cartridge are then screwed 
back together, and the instrument is then fired after releasing the safety lever. 
This maneuver creates a simultaneously full thickness esophageal resection and 
an end to end anastomosis of the distal oesophagus with two double rows of 
staggered circular staples (Fig 3). The anvil is then separated from the 
cartridge and the instrument is extracted from the gastrotomy incision with 
gentle rotation. The instrument is then carefully checked for possible retained 
staples, and more importantly, the resected ring of the esophagus is examined to 
ensure the completeness of the procedure. The stomach is then irrigated with 
Fig 3: Demonstrating the oesophageal resection maneuver using the EEA 
stapler 
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copius amounts of saline solution and checked for any additional bleeding. 
Specific attention is paid to the gastric varices, and when found, are ligated in 
situ using #000 silk suture material. The gastrotomy opening is then closed with 
a TA-90 stapler or if smaller mouth with a TA-55. 
Operative time, vital signs and total blood loss are carefully assessed at 
this point and if the patient is judged to be stable by both the anesthesiologist 
and the operating surgeon, a splenectomy is performed if it is technically 
feasible. Mesenteric vein pressure are performed prior to the splenectomy and 
immediately after. If the patient remains stable at this point, and blood loss 
is less than 400 ml, the posterior vagus is then transected between metal clips 
and a pyloromyotomy is performed. A . needle biopsy of the liver is always 
performed prior to closure of the abdomen. A nasogastric tube is then passed 
into the antrum and left in that position. The abdomen is closed without drains 
using nonabsorbable heavy suture material and retention sutures. Postoperatively, 
the patients are maintained on a chronic regimen of Propranolol. 
The combined procedure was performed in only four out of the five patients. 
It was not performed on the last patient because of the patient's tenuous status 
during surgery. 
Results 
Variceal bleeding was totally cantrall ed after the procedure and no 
anastomotic leaks or disruptions occurred. One patient developed stenosis at the 
anastomotic site which responded very nicely to esophageal dilatation which was 
performed three weeks after surgery. In four patients the variceal regression 
was endoscopically confirmed postoperatively, as well as demonstrated 
radiographically. Operative time averaged one hour and fifteen minutes. The 
intraoperative blood 1 oss ranged from 250 ml to 550 ml. 0 ne patient who only had 
the esophageal stapling procedure performed, and was in a Child's C 
Classification, died ten days postoperatively from combined renal and liver 
failure. The other four patients who had been followed for up to thirteen months 
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postoperatively had no evidence of bleeding from any gastrointestinal origin. 
Discussion 
The cirrhotic patient who presents himself at the hospital today bleeding 
from esophageal varices can expect to be treated medically first by the use of 
intravenous vasopressant 
70°/a chance of resuming 
and balloon tamponade procedures. This patient stands a 
active bleeding within a few days after the balloon is 
deflated. This patient will probably continue to be treated medically and even 
with multiple transfusions, deteriorate to the point that even the bravest of 
surgeons will be reluctant to operate, especially when ascites, encephalopathy 
and jaundice 
mortality rate 
are present. Even under the best of circumstances, the operative 
for such emergency procedures of all descriptions range from 40% 
to 80%. In a series of 146 patients who underwent emergency portocaval shunts, 
Orloff (1975) reported a 46.6% mortality rate, his operative time averaged 4.2 
hours with over 10 units of blood used on each patient. Bleeding promptly 
stopped in the group of patients, and the portal venous pressure reduced by 1/3, 
hepatic failure was the cause of death in 55% of the patients. It is apparent by 
the length of the operative procedure, and the amount of blood used during the 
patient 1 s hospitalization, that such a procedure would not be feasible for the 
Jehovah 1 S Witness patient. 
In 1967, Warren described the selective distal splenorenal shunt which was 
designed to reduce the pressure in the portal system while preserving flow to the 
liver. The procedure was also designed to decompress the gastroesophageal 
submucosal plexus. The results of this procedure were better than other shunting 
procedures with regards to liver insufficiencies following the procedure, but it 
is 1 eng thy and can be bloody as well. Overall survival rates are better in 
nonalcoholic as opposed to the alcoholic patient. This type of shunt is poorly 
suited for use in the emergency decompression of varices in elderly patients and 
patients with refractory ascites, severe impainnent of liver function and in 
patients where blood transfusions could not be employed. 
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Mesocaval shunts employing a prosthetic graft between the superior mesenteric 
vein and the vena cava failed to show any superiority over side to side 
portocaval shunts except from some technical consideration. This type of shunt 
carries with it a high rate of thrombosis. Emergency mesocaval shunts have been 
shown to carry with it a 73% mortality rate. 
It is generally agreed that there is little, if any, use for prophylactic 
porto-systemic shunting. Even in patients in whom elective shunts have been 
performed there was no prolongation in the overall survival time, as compared 
with the medically treated patients. There has been no changes demonstrated in 
liver functions that could be related to the decompression procedure. 
Because of the high mortality rate associated with emergency shunting 
procedures, a variety of nonshunting procedures have been atte111pted to control 
variceal bleeding when the medical treatment failed to accomplish it. The 
transthoracic ligation of the bleeding varices offered such a direct approach 
without interfering with portal flow. Although the advantages of such a 
procedure is a rapid and early control of the bleeding source, the disadvantages 
of a thoracotomy, esophagotomy in a sick patient were over~<helming. Orloff 
reported that only 54% of the patients subjected to the Boerema procedure 
survived it. 
The Mil nes-Walker mucosal transection procedure resulted in a similar higher 
mortality rate of 55%. It also included such complications as esophageal leaks, 
respiratory failure, severe gastritis with bleeding and mucosal tear. 
The Sugi ura procedure of gastric devascul ari zati on, esophageal diversion, 
variceal ligation and reanastomosisJ while perhaps a good alternative to a 
decompression procedure, is stil1 a major surgical procedure which is not suited 
to the actively bleeding, ill cirrhotic patient and certainly not in a Jehovah's 
Witness patient (Sugiura and Futagawa, 1977). 
In 1974, Van Kemme] reported the first esophageal transection and 
reanastomosis using a Russian staple gun. His results were good even though 
eight of his twenty-one survivors developed esophageal strictures which responded 
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to dilatation. There were no anastomotic leaks and no postoperative bleeding. 
Similar good results were obtained by Johnson in 1977 using the Russian FT-TU 
stapling gun. 
The introduction of the EEA stapler by the U.S. Surgical Corporation was 
stimulus enough for many investigators to try it in the performance of esophageal 
transection. In contrast to the early Russian instrument which contained only a 
single row of 12 hand-loaded metal staples and only a 26 mm cartridge size, the 
EEA stapler comes in various sizes of the cartridges containing preloaded double 
rows of 30 staggered staples. 
In 1980, Cooperman et al. reported their results with five cirrhotic patients 
on whom they transected and reanastomosed the esophagus using an EEA instrument; 
one patient died postoperatively from renal failure, and the other four did well 
and were discharged without evidence of further variceal bleeding. Wexler 
(1980), in a similar series, but on a much sicker group of patients, also 
reported a complete control of variceal bleeding using this ~nethod. His 
mortality rate was much higher, however. 
The procedure employing the EEA stapler as well as its modification by 
Rinecker-Danek (1975) using the GIA instrument without the dividing blade, causes 
obliteration of the submucosal plexus of veins, as well as the plexus between the 
muscle layers of the esophagus. It does not, however, interrupt the 
periesophageal plexus. This fact may not be detrimental if the procedure stands 
the test of time, and the patients do not continue to bleed. The only procedure 
which divides all three plexus of veins is the Sugiura devascularization 
procedure which would not be applicable to the group of patients that we were 
involved with. 
Our experience, as well as other investigators using the EEA technique, shows 
it to be an easy, quick, simple and very effective way of controlling bleeding 
esophageal varices. It can be accomplished with less than a unit of blood loss 
intraoperatively and with an operative time of one hour. 
We have added a posterior vagotomy and pyloromyotomy and splenectomy to our 
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procedure, as well as maintaining these patients chronically on Propano1o1 
(Inderal), because of the special nature of this group of patients which we were 
involved with. The reasoning behind this approach has been an attempt to combine 
the initial bleeding control procedure in an intraoperative stable patient, with 
other modalities which will cause lowering and maintaining a lower portal 
pressure, as well as decrease the reportedly higher incidence of bleeding from 
peptic disease seen in cirrhotic patients, as compared with the general 
population. 
It has 
1 owe red 
attempted 
emp 1 oyed 
been our experience that performing a splenectomy in a patient has 
the portal pressure by 25%. A similar approach to the problem has been 
by ligating the splenic artery, and further modifications have been 
by Delguercio ( 1981) even though his technique is somewhat different 
from ours. 
Adding a posterior vagotomy (since we make no attempt to avoid the tran-
section of the anterior vagus during the initial stapling procedure) and a 
pyloromyotomy adds 1 i ttl e to the operative time and the blood 1 oss. It does, 
however, give an added assurance of decreasing the incidents of bleeding from 
peptic disease in this group of patients in whom bleeding must be avoided at all 
costs. 
Numerous articles in the medical literature have pointed out the beneficial 
effect of Propanolol in decreasing variceal bleeding by producing a sustained 
reduction in portal venous pressure in cirrhotic patients with portal hyper-
tension. The dose of propanolol needed to produce an effective drop in portal 
pressure must be titrated so that it also produces a drop of approximately 25% in 
heart rate in those patients. The drop in the cardiac output is thought to cause 
a decrease in splanchnic blood flow which in turn causes a drop in portal 
pressure. 
We recognize the fact that not 
bleeding is a surgical candidate. 
every cirrhotic patient who has variceal 
For those judged to be too sick to undergo 
surgery, a few nonoperative modalities are fortunately available. One modality 
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is the transhepatic percutaneous embolisation of the coronary vein. The other is 
sclerotherapy through a flexible endoscope. Both procedures can be accomplished 
without the use of general anesthesia and should be a part of the physician's 
armamentarium when treating patients with this complex problem. 
Our results to date have been encouraging, however, we recognize the fact 
that we do not have a long-term follow-up on these patients. We have attempted 
to combine a number of potentially therapeutic modalities within the framework 
and the limitation imposed upon us by the religious dictates of our patients. We 
can only hope that other investigators will continue to explore the same or other 
approaches to this complex problem and provide a larger data base from which 
concrete conclusions may be drawn in the future. 
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!!-iii Internal Iliac Artery Ligation: Analysis of Fifty Cases 
The technique of internal iliac {hypogastric) arterial ligation for the 
purpose of controlling pelvic t1emorrhage has been known for nearly ninety 
years. Its effectiveness has been proven by many authors. The purpose of 
this manuscript is to report our experience with this technique in the 
surgical management of the Jehovah 1 s Witness patient in whom the decrease 
of intraoperative blood loss is paramount, as well as report on an unusual 
case where the patient would not have survived without this procedure. 
r~ateri al and Methods 
The data for this report was obtai ned from our persona 1 su rgi ca 1 
experience with over 5,000 Jehovah's Witness patients during the period 
beginning in September 1973 and ending in March 1983. 
Table Ill illustrates the number of patients on whom ligation was 
carried out, the primary diagnosis and the complications which occurred 
following the ligation. 
Results 
Our experience has demonstrated that no tissue necrosis occurred 
following the ligation procedures in 50 patients. In only three cases did 
we notice transient bladder atony. We had no intraoperative mortalities 
and noticed no significant postoperative complications in this group of 
patients. We are convinced that the patient {P.E.) which is reported 
below, would not have survived without employing bilateral retroperitoneal 
hypogastric arterial ligation. 
Discussion 
Ligation of the internal iliac arteries to control pelvic bleeding was 
first performed by Kelly in 1894. Kelly believed the procedure to be bold 
Table Ill 
DIAGNOSIS NUMBER 
OF CASES 
Carcinoma of the bladder 
combined cystectomy with ileal loop 4 
Postoperative bleeding following 
vaginal hysterectomy 3 
Carcinoma of the bladder. 
Control of hemorrhage 5 
Recurrent pelvic tumors (gynecological) 
with hemorrhage 12 
Bleeding from extensive carcinoma of 
the rectum 2 
Hemorrhage following childbirth 
complications 2 
Carcinoma of the rectum. Combined 
with abdominal-perineal resection 15 
Combined with difficult hysterectomies 7 
Total Number of Cases 50 
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COMPLICATIONS 
None 
Bladder atony developed 
in one patient 
None 
Transient bladder atony 
developed in two patients 
None 
None 
None 
None 
Overview of patients undergoing Internal Iliac Artery Ligation and the complications 
resulting from the procedure. 
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and dangerous as he felt, as many still do, that this completely shut off the 
blood supply to the pelvis (Burchell, 1968; Pelosi et al. 1976}. Many of the 
concepts of the physiology of the pelvic circulation were based on experience 
with the circulatory system in other areas of the body. In the extremities, 
sudden occlusion of the main blood supply leaves distal tissue with inadequate 
collateral circulation and leads to tissue necrosis. The physiology of the blood 
supply in the pelvis is entirely different and ligation of the internal iliacs 
leads to infrequent and relatively minor complications. 
The blood supply to the pelvis is amazingly abundant. The internal iliac 
artery supplies blood to the wall and viscera of the pelvis, the reproductive 
organs, the buttocks, and the inner aspect of the thigh. The artery arises at 
the bifurcation of the common iliac, descends into the true pelvis, and divides 
into the interior and posterior divisions. The branches of the internal iliac 
are highly variable. In the most common pattern, the ilio-lumbar, lateral 
sacral, and superior gluteal arteries spring from the posterior division. The 
inferior gluteal, internal pudendal. inferior vesicular) superior vesicular, 
obturator, middle 
division (Pelosi 
rectal, vaginal. and uterine arteries spring from the anterior 
et al. 1976; Grants Atlas of Anatomy, 1978). All of these 
arteries anastamose extensively, but there are three major collateral systems. 
They are the lumbar, ilio-lumbars, middle sacral, lateral sacral, and superior 
hemorrhoidal, middle hemorrhoidal arterial anastomosis (Berlind, 1966). 
Burchell, with some elegant work in the 1960's, must be credited for 
discovering much of what is known about the physiology of the pelvic circulation 
today. He found that following ligation of the internal iliac arteries, the 
uterine artery continued to bleed freely after being cut, but that he was able to 
easily stop the bleeding with pressure alone. He subsequently took pressure and 
flow readings pre- and post-ligation on a series of patients and discovered there 
was an 85% drop in pulse pressure, a 24% drop in mean arterial pressure, and a 
48% drop in flow post ligation. The ligation changed the pelvic arterial system 
into a system with flovJ characteristics very similar to that of a venous system 
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(Burchell, 1968). 
Interestingly 
and f1 ow on 
enough, with unilateral ligation, the drop in pulse pressure 
the contra] ateral side are minimal. The co11 ateral system is mainly 
a vertical one with very few horizontal anastamosis. Burchell (1968) followed 
the pressure and flow readings with arteriography. The arteriography confirmed 
what the pressure and flow measurements indicated, that the collateral 
circulation of the pelvis is well developed and ligation of the iliacs deprived 
no pelvic structures of blood. The blood, rather than going through the internal 
iliacs to arterial branches to col laterals, reversed direction and went from the 
co1latera1s to arterial branches to the internal iliacs. No artery was without 
adequate blood flow (Burchell, 1968). Several patients were followed up with 
arteriography several years following bilateral internal iliac ligation. It was 
found that the iliacs remained occluded and the co11atera1s did not hypertrophy 
with time. This indicated that the initial blood supply, following ligation, was 
adequate, so that no compensatory growth of the collateral system was necessary 
(Burchell 1968). 
There have been 
following internal 
several reports in the literature of successful pregnancy 
iliac ligation. Shinagawa et al. (1981) reported two cases of 
successful pregnancy following 1 i gati on 
infundibulipelvic ligaments. The facts 
a pregnancy can 
bil atera11y of both internal i 1 i acs on 
that there is no compensatory growth of 
be nourished to successful completio~ collaterals and that 
following ligation of 
pelvic blood supply. 
the internal iliacs illustrates the vast abundance of the 
Complications related to this procedure are infrequent and therefore rarely 
occur are usually mild and transient. Alleged reported and when they 
complications 
atonic bladder 
al, 1976). 
are ureteral and vesicular fistulas, necrosis of the buttocks, 
and circulatory disturbances of the lower extremities (Pelosi et 
Sack's review of 48 cases of ligation of the internal iliacs reported 
transient atonic bladder (4 patients) lasting four days and claudication of 
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buttocks and thighs (1 patient) lasting several weeks that was associated with 
long standing hypertensive disease (Sack 1973). Lash reported 115 bilateral 
internal iliac ligations prior to t"adi cal hysterectomy for cervical carcinoma .. 
They reported a significantly higher incidence of bladder atony in those patients 
with iliac ligation compared to controls and a slightly higher rate of 
ureterovaginal fistulas. The fistulas were all associated with radiation therapy 
which increases the avascularity of pelvic structures (Lash and MacNerland 1970). 
Both Sack and Lash found this procedure to be life saving in the treatment of 
uncontrollable pelvic hemorrhage and only questioned its use prophyl acti cal1y and 
for teaching purposes. 
Paploucas (1971) {12 patients), Burchell (1967) (45 patients), Staples {1973) 
(1966) (1 patient), and Pelosi (1976) reported no { 60 patients), Berl i nd 
complications secondary to internal iliac artery ligation. 
Necrosis is a rare complication and does not occur in a normal pelvis. It 
only occurs if a number of collateral pathways are destroyed (Burchell 1968). 
Our population of patients consists mostly of Jehovah's Witnesses who for 
religious reasons, 
complications of 
refuse 
internal 
to accept blood transfusions. In this population, the 
iliac ligation, i.e. bladder atony and fistula 
formation, which we have seldom experienced, 
tubular necrosis, congestive heart failure, 
are minor compared with acute 
and shock lung associated with 
hypovolemic shock which can result from severe pelvic !1emorrhage and inability to 
replace blood loss. In patients with severe pelvic hemorrhage who are willing to 
accept blood transfusions, the above complications are acceptable if the bleeding 
is severe enough 
acute respiratory 
and the complications of hepatitis, transfusion reactions, and 
distress syndrome which can occur fo1lowing massive 
transfusions are considered. 
We feel that the benefits of 1 i gati on of the internal iliac arteries to 
control pelvic bleeding far outweigh the complications. lf carried out by 
competent surgeons, the procedure is safe and effective. 
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CASE REPORT 
P.E., a 29 year old Jehovah's Witness female, Para 2, Gravida 2, who on 
February 11, 1982 delivered a 6 lb 9 oz girl. During the delivery, the patients 
uterus ruptured and she rapidly went into hypovolemic shock. Because she refused 
to accept blood transfusions as a part of her medical treatment, she was 
transferred to Bellflower City Hospital with a hemoglobin of 1.7 gm %. Her blood 
pressure was 40/70 mm Hg which was partially maintained by the use of shock 
trousers, pulse was 140 and respirations were 28/min and shallow. Because she 
was actively bleeding after her arrival via emergency air transport, she was 
taken to surgery in an attempt to control the bleeding. Because of her extremely 
critical condition, it was decided not to attempt to perform a hysterectomy but 
rather to 1 i gate both internal iliac arteries through a retroperitoneal approach. 
Anesthesia was successfully carried out using intravenous Valium, Ketamine and 
short acting muscle relaxant. Intraoperative blood loss was approximately 20 cc. 
Postoperatively, the patient, who did not receive Fluosol-DA 20%, received 
intravenous iron dextran, folic acid and intramuscular injections of nandrelone 
decanoate and B-12. Hydroxyethyl starch was employed for volume expansion. The 
patient 1 s hospital course was uneventful and she was discharged on the tenth 
postoperative day with a hemoglobin of 7.9 gms %. 
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CHAPTER II I 
GENERAL ANESTHESIA FOR THE ANEMIC PATIENT WITHOUT BLOOD TRANSFUSION. 
Our experience includes over 5000 Jehovah 1 s Witness patients who underwent 
general anaesthesia for major surgery without the use of blood or blood products. 
These patients tolerated low hemoglobin and hematocrit levels remarkably well. 
We had one patient who underwent surgery and general anesthesia with a hemoglobin 
level of 1.7 gms hemoglobin and survived. 
Other physicians have reported similar experiences treating Jehovah 1 S Witnesses. 
Ott and Cooley {1977), reported a series of 542 patients in whom cardio-
vascular surgery was performed without the use of blood or blood products. The 
bubble oxygenators that were employed were all primed with Ringer's Lactate 
solutions. Considering the procedures performed and the preoperative status of 
the patients, the authors produced very good results. 
Rush and Eiseman {1967) studied the effects of hemodilution with lactated 
Ringer's solution in dogs subjected to graded hsnorrhages. A four-fold volume 
replacement for 60% exsanguination resulted in survival, while such replacement 
after 75% hemorrhage was fatal for the dogs within 24 hours. Moss (1969) 
subjected splenectomized dogs to sequential 36%, 60%, and 75% hsnorrhages. In 
this series the animals were stabilized after each hemorrhage and relatively more 
lactated Ringer's was given according to their urinary output. The author 
emphasized that adequate hemodilution was reflected by good urinary output; all 
of his dogs were long tenn survivors. 
In view of the above mentioned results of both clinical and experimental 
studies, it is becoming clear that the blood bank is being grossly overused. On 
the basis of retrospective analysis, it has been calculated that about 40% of all 
transfusions are unnecessary. It is the authors opinion that over 85% of all 
transfusions are not indicated and therefore should not be performed in view of 
the great risks involved. 
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Since we primarily deal with Jehovah 1 5 Witnesses~ we have asked ourselves 
certain fundamental questions: 
1. How do we best prepare a patient that cannot receive blood or blood 
products for surgery and general anesthesia? 
2. What is the best anesthetic technique for patients with low 
hemoglobin levels? 
3. What are the lower 1 imi ts of oxygen carrying capacity that a patient 
can survive during general anesthesia? 
4. What other choices do we have for severely anemic patients 
undergoing surgery? 
The definitive treatment of acute hypovolemia must be early replacement of 
intravascular volume, and oxygen supplementation. If the patient shows signs of 
hypovolemia, indicated by a low systolic blood pressure, increased heart rate, 
low central venous pressure, or urinary output of less than 1 m1 per minute. we 
like to employ the early use of Hespan (hydroxyethyl substituted amylopectin) 
Depending on the values of the abovementioned parameters, 500 to 1,000 of Hespan 
is administered, 
This colloid solution is chosen for the following reasons: 
1. It is an effective plasma volume expander with characteristics 
similar to those of human serum albumin. 
2. Effects persist for 24-36 hOurs. 
3. It is nearly free of allergic and untoward effects. 
4. It has been used for thirteen years at M.D. Anderson Hospital, 
Houston, Texas, with no anaphylactoid reactions having been 
observed. 
Hespan, marketed 
starch in 0.9% of 
has minimum effects 
by American McGraw Laboratories, is a 6% solution of heta-
sodium chloride. If given in doses not exceeding 1500 ml, it 
on the coagulation mechanisms. This colloid also is a 
fraction of the cost of albumin. 
Next, we give Dextrose 5% in Lactated Ringer's solution 1000 ml followed by 
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1000 ml of Ami nosyn 3.5% - the 1 atter· contains a 11 the essenti a 1 ami no acids. 
Finally, we slowly give a solution that is high in potassium chloride, 
Electrolyte #75. The regimen assures that the patient has received proper pro-
portions of colloid and crystalloid to maintain intravascular oncotic pressure 
and electrolyte balance, as well as isotonic interstitial fluid space require-
ments. 
Uri nary output is an excellent guide to adequacy or hemodilution in patients 
not receiving blood or blood products. If the patient is not excreting urine at 
the rate of a least 1 ml per minute~ regardless of other parameters, then more 
fluids are indicated (e.g. Dextrose 5% Lactated Ringer's Solution). The fluid 
regimen we have described can usually be completed even in emergency procedures. 
In our experience, time is of the utmost importance. Firstly, the patients 
initial blood loss must be rapidly replaced with crystalloid and colloid 
solutions. Secondly, if possible, surgery should be delayed 1 ong enough for the 
patient to reconstitute his vascular proteins (albumin), and for the institution 
of a regime designed to accelerate hemoglobin formation. This regime consists of 
the administration of intravenous iron dextran and folic acid, and intramuscular 
injections of Vitarni n B-12 and nandrel one decanoate, an anabolic hormone. After 
a 1 ag 
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period of 24 hours, hemoglobin concentrations rise at an average rate of 
gms per day. Therefore, the more time we have to treat an anemic patient 
prior to surgery the better anesthetic risk he becomes. 
If the patient is hypovolemic and s,urgery must be performed, the anesthetic 
induction period 
agent that does 
is of critical importance. It is important to use an induction 
not produce peripheral vaso-dilatation or cardiac depressor. If 
such an agent is used, this would lead to a severe drop in venous pressure and a 
reduction in cardiac output with possible fatal results in the severely anemic 
patient. 
We have found that, when inducing anaesthesia in the critically ill or 
severely anemic patient, the admi ni strati on at a combination of Diazepam and 
Ketamine has advantages in that, not only are amnesia and hypnosis produced, but 
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also a strong analgetic effect is caused. Furthermore, Ketamine is a myocardial 
stimulant that raises blood pressure} cardiac output, and heart rate but does not 
depress respiration. The occurrence of emergence delirium, hypertension and 
tachycardia are undesirable effects that may be produced by the drug. The first 
of these negative characteristics can be largely blocked by Diazepam 5 to 15 mg 
intravenously, as 
al. (1974) have 
demonstrated by Dundee and Lillburn (1977). Zsigmond et first 
shown that tachycardia and hypertension are caused by elevated 
primarily of norepi neph ri ne, and that this can also be catecholamine levels, 
blocked by Diazepam. 
The patient is preoxygenated and while breathing 100% oxygen, small 
increments of Diazepam (5 to 15 mg total dose) and Ketamine (50 to 75 mg total 
dose) are slowly administered by the intravenous route. When induction is 
complete, rapid intubation is performed with the aid of a short acting 
depolarizing muscle relaxant. We have found that when Ketamine is used in this 
fashion, there is little or no cardiovascular stimulation. 
After induction, most patients require minimal amounts of inhalational 
anesthesia. We use an oxygen-isofurane technique. We have now used this drug on 
several hundred patients and like it for several reasons. Isofurane has a lower 
blood-gas partition coefficient (1:4}, than Enflurane (1:9), or Halothane 
(1:3.6). This means that the depth of anesthesia can be changed more rapidly and 
with greater safety. Elimination from the lungs is also more rapid, and the 
patients are usually able to respond to commands within 12 minutes after the 
anesthetic has been discontinued. Secondly, Isofurane has relatively little 
effect on the myocardium. In normocapnic patients, 1 to 2 MAC Isofurane does not 
significantly decrease cardiac output, whereas, over the same range (l to 2 MAC), 
Halothane and Enflurane decrease output by 20 to 30%. 
In addition to an- absence of myocardial depression under isofurane, no 
increased incidence of ventricular arrythmias is noted under the influence of 
this agent. Although there is a decrease of 15 to 20 mm Hg in systolic arterial 
pressure, this decreases left ventricular work and myocardial oxygen consumption 
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by up to fifty percent at deeper levels of anesthesia. This is obviously 
beneficial for our anemic patients. The 20% increase in heart rate, is abolished 
by moderate doses of narcotics such as 0,1 or 0,2 mg of Fentanyl. For the above 
reasons, Isofurane is our choice for patients with impaired myocardial perfusion 
and/or function (CHF). We are so pleased with this agent that we use it almost 
exclusively in all our adult patients, anemic or not. 
Muscular relaxation under anesthesia is secured by the use of an intravenous 
suxamethonium (2 mg/ml). A supplemental narcotic is often given depending on the 
patients intraoperative condition. We like Fentanyl because of its rapid onset, 
short duration of action and lack of cardiac depressant properties. As is the 
case with Diazepam it also prevents the adverse hyperdynamic cardiac response to 
a ketamine induction. There is also evidence that it blocks the stress hormone 
responses of surgical trauma. Laryngeal and tracheal reflexes are depressed 
faci 1 itati ng the intraoperative and postoperative management of the intubated 
patient. In short, Fentanyl supplementation provides a smooth and safe 
anesthetic which can result in an awake and pain free patient in the immediate 
postoperative period. 
In our experience with over 5,000 patients of the Jehovah 1 S Witness faith~ we 
found very few who needed blood or blood products. It seems clear that most 
adult patients can undergo rapid loss of 1000 to 2000 ml of blood. They will not 
go into irreversible shock if hemodilution is adequate. Cellular elements are 
rarely needed even 
platelet reserves 
circulation during 
after extensive blood loss of 2000 ml or more. Leukocyte and 
are such that there is a rapid outpouring of each into the 
and immediately after any significant bleeding. In our 
experience, thrombocytopenia and leukopenia are rarely a problem. 
The ultimate survival of the patient is determined by the relationship 
between a decreasing oxygen carrying capacity of blood and myocardial oxygen 
need. The extent to which a patient can compensate for anemia is dependent upon 
his reserves. The patient with a low hemoglobin has a decrease in blood 
viscosity, a shift in the oxyhemoglobin dissociation curve to the right, an 
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increased oxygen extraction by various organs, an increased erythropoietin 
production, an increased vasomotor response and an increased cardiac output. This 
increase in cardiac output is only possible if the patient is hemodiluted to 
nonnovol emi a. Because heart rate changes only slightly with adequate fluid 
replacement, the increase in cardiac output is due to an increase in stroke 
volume associated with increased venous return. If there is an increase in heart 
rate with a small increase in cardiac output, then the patient is sti 11 probably 
hypovolemic. 
Andrews et al. (1980) state that coronary blood flow is nonnally highly 
privileged to 
blood flow is 
prevent 
out of 
response to anemia, as 
authors further state 
any fall in coronary sinus p02. This increase in coronary 
proportion to relative increases in cardiac output in 
long as the hematocrit does not fall below 20%. These 
that increased tissue extraction of oxygen and shift of 
oxy-hemoglobin dissociation curve to the right occur at hematocrits below 20%, or 
when hemodilution is associated with hypovolemia. Furthermore, it appears that at 
hematocrits in this range there is a more homologous distribution of oxygen to 
tissues. 
As previously mentioned, myocardial performance is the other key determinate 
in maintaining adequate tissue oxygenation. The heart normally utilizes 65 to 
70% of the oxygen available in coronary arterial blood, the brain extracts 
one-third and the kidneys less than 10%. Therefore, oxygen to the myocardium is 
the weakest 1 ink in allowing our patients to respond to anemia. If hemodilution 
is inadequate or if started too late, the return of stagnant peripheral, hypoxic, 
and acidotic blood into the circulation lowers cardiac output and aggravates the 
situation further. A negative cycle can be started in which a hypoxic myocardium 
leads to further increases in hypoxia due to decreased cardiac output. If this 
cycle is believed to be in effect or even pending, Sodium Bicarbonate, high dose 
steroids, and digitalization may be indicated if the patient can not receive 
blood. 
The availability of Fluosol-DA 20% for increasing the blood's oxygen carrying 
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capacity may greatly help in the preoperative preparation of the Jehovah's 
Witness patient. Our results with nine anemic patients with hemoglobins of 8.0 
gms or less were very encouraging. All nine patients tolerated surgery although 
the most severly anemic patient, who had a haemoglobin concentration of 1,9 gm%, 
died on the fifth postoperative day from complications unrelated to the Fluosol 
therapy. Another patient, aged 75 years, (mean Hb = 6.2 gm%) with severe cardio-
pulmonary disease died three weeks postoperatively. This again was unrelated to 
the Fl uosol therapy. This substance as well as a new generation of 
perfluorocarbons called Fluosol-DA 35-2, which can be stored in an unfrozen state 
and used without the need of high Pa02 tensions, could greatly improve our 
ability to treat the severely anemic patient. 
In conclusion, we believe blood and its products have been overused in the 
past and are still presently being overused. Furthermore, we have demonstrated 
viable alternatives to blood therapy in the anemic patient who needs surgery. 
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CHAPTER IV 
METHODS OF AVOIDING BLOOD TRANSFUSION 
IV-i Intraoperative reinfusion 
Introduction 
In spite of the current interest in intraoperative reinfusion and the acknow-
ledged benefits of the autologous versus homologous transfusions, this approach 
towards blood conservation and minimizing the risks inherent to blood trans-
fusions (Table IV) has not received the recognition which it properly deserves. 
Reluctance by surgeons to use this technique is undoubtedly due to the confusion 
which still exists in the literature regarding the possibility of complications 
in using this procedure. Widely divergent hematological abnormalities in the 
form of various coagulopathies and hypofibrinogenemia still appear in medical 
communications. 
It is the purpose of this part of the thesis to report and extensively 
discuss our experience with .this technique in the past seven years. Our 
experience involved a total of 758 patients. Although the majority of this 
experience involved the cell saver apparatus (manufactured by the Hemonetic 
Corporation), we have also had some experience with the ATS-100, (manufactured by 
Bentley). We will attempt to discuss each separately, as well as compare their 
perfonnance. 
Materials and Methods 
Seven hundred and fifty eight patients undergoing cardiac, orthopaedic, 
thoracic, urological and general surgical procedures have been subjected to 
intraoperative autotransfusion when this modality of treatment was acceptable to 
the individual patient. Three hundred and seventy-four patients had open heart 
procedures, three hundred and thirty-one had orthopaedic procedures and fifty-
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Table IV: POTENTIAL PROBLEMS IN TRANSFUSION THERAPY 
----
Type Cause In Vivo Symploms Prognosis Action Pre\lention 
Hemolytic Reactions 
Immediate Lysis of donor Direct attack Pain a! infusion Life-threat- Stop tmns- Careful adherence to 
cells by anti- on transfused site; flank pain; ening, fusion; give testing and transfusion 
body red cells by fever (with or sometimes mannitol or protocols. Stan tram.-
recipient anti- wirhout chills); fatal furosemide; fusion slowly and ob-
body and chest pain: hypo- maintain serve patient closely 
complement tension/shock; urinary flow for tirst 15 minutes 
with intra- dyspnea; flush-
vascular and ing: excessive 
extravascular oozing of blood: 
destruction. hemoglobinuria 
Hemoglobin 
is released 
Delayed Lysis of donor A prior expo- Decreased hemo- Usually Identify Thorough investigation 
cells by anti- sure to antigen globin; increased mild. but causative of all suspected anti-
body 1-2 produced no bilirubin; posi- can be life- factors; sup- bodies_ Proper use. of 
weeks after detectable tive direct ailti- threatening pon the pa- universal donor blood 
transfusion antibody. A globulin: anuria tient with 
second stimu- or oliguria; hypo- all mea-
Jus (transfu- tension/shock sures. as in 
sion) pro- an immedi-
duces anti- diate reac-
body which tion, if 
lyses the still necessary 
circulating 
crossmatched 
cells 
lnterdonor Lysis of donor Destruction of Mild !0 severe Mild (de- Stop trans- Do not transfuse blood 
cells by previ- some or all of pends on fusion containing hemolytic 
ously trans- the new donor serologic antibodies. Use PRBC 
fused antibody cells character- with most of plasma 
istics of the removed. 
antibody) 
to severe 
with anuria 
Lysis of Antibody in Small amount Mild to none Mild to Stop trans- Use packed red .blood 
Recipient donor plasma of antibody severe fusion cells 
Cells by destroys recip- bound due w 
Passively ient red cells excess amount 
Antibody of antigen. 
Antibody di-
luted in pa· 
tient · s plasma 
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Table IV: POTENTIAL I'IIOIILEMS IN TRANSFUSION TIIEIIAi'Y (CONTINUED) 
Type Cause In Vivo Symptoms Prognosis Action Prevention 
Nonhemolytic Reactions 
Febrile Amileukocyte Plugging of Mild: chills, Usually not Stop trans- Use leukocyte poor or 
anlibody; ami- pulmonary fever, headache, life threat- fusion; anti- frozen red blood cells 
platelet anti- vessels by leu- myalgia, nausea ening, aJ- pyretics, 
body. ami- kocyte anti- Severe: hypoten- though antihista-
serum protein gen-amibody sion. chest pain, symptoms mines, sup-
antibody complexes; dyspnea, vomiting can be port patient, 
focal vascu- severe investigate 
lar injury cause (full 
causing fluid workup) 
exudation into 
lung tissue. 
Damage re-
leases pyro-
gens 
Allergic Allergens in Transfused Mild: urticaria. Mild to life- Stop trans- Use frozen deglycero-
transfused aniigen binds facial swelling threatening fusion; trear lized or washed red 
blood (lgE to mast cells, Severe: dyspnea, life threat- cells; use IgA deficient 
antibody); his- causing dis- hypotension, ening symp- plasma 
toi'y of patient ruption and laryng!!al edema, roms; di-
allergy; trans- release of his- substem-chest phenhydra-
fusing lgA to tamine and pain, shock mine (paren-
IgA deficient serolonin teral), epine-
patients phrine, 
corti-
cosreroids 
Circula10ry Blood volume Congestive Tightness in Good if Slow or stop Give PRBC, monitor 
Overload too large for heart failure, chest, dyspnea, treated early transfusion, transfusion, give slow 
pumping ac- pulmonary basilar rales, diuretics, transfusions in divided 
tion of heart edema diaphoresis rotating units 
tourniquets, 
patient in 
sitting 
position, ad-
minister 
oxygen, 
monitor 
vital signs 
Contami- Bacterial Produces exo- Fever, shaking Poor Smp trans- Asceptic collection 
nared Blood growth ( usu- toxins chills, abdomi- fusion, technique proper and 
ally gram nai pain, pain in parenteral continuous refrigera-
negative) extremities, antibiotics, tion of blood from col-
vomiting, bloody vasopres- lection to lransfusion, 
diarrhea, hypo- sors, corti- careful visual examina-
tension costeroids, tion of blood prior m 
fh.r.ids, transfusion, use only 
electrolytes inline blood wanners 
44 
Table IV: POTENTIAL PROBLEMS IN TRANSFUSION THERAPY !CONTINUED! 
Typ< Cause In Vivo 
Nonhemolytic Reactions 
Air Air introduc~ Blood be-
Embolism tion into comes frothy 
venous sys- and cannot be 
tern during pumped by 
transfusion the heart 
Lysis Mechanical Hemolysed 
(Nonhemo- trauma, os- red cells 
lytic) marie dam-
age, thermal 
extremes 
Symptoms Prognosis 
Dyspnea, cya- Pom 
nosis, shock, 
cardiac arrest 
Eleva1ed bilirubin Good-de-
pends on ex-
tem of 
damage 
Action 
Stop trans-
fu:;ion, posi-
lion patient 
on left side 
with head 
lowered. 
trea! shock/ 
cardiac 
arrest 
Stop trans-
fusion, sup-
port patient, 
correct 
problem 
Prevention 
Avoid introdw.:tion of 
air into tubing, Jo not 
change transfusion set 
imraprocedure 
Avoid obstruction of 
blood flow (check for 
kinked lUbing). use 
only isotonic normal 
saline as staner solu-
tion, use properly se! 
blood warmer~ and 
avoid ex.tremes of 
temperature during 
storage and handling 
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three had miscellaneous procedures. These patients were treated in two small 
community hospitals with a total bed capacity of 375 beds. In 46 patients, the 
ATS-100 was either actively used or kept on a standby basis. The rest of the 
patients were treated by the cell saver. 
We wi 11 examine and report at 1 ength on the first 100 orthopaedic procedures, 
which we included in this series (Table V). Nine patients were omitted due to 
1 ack of data. ProTime, PTT, 23 DPG, and electrolytes were estimated pre- and 
postoperatively and found to be within normal limits. The average red blood cell 
recovery in the first 100 patients was a disappointing 43r,, as measured by the 
hematocrit value. In the next 131 patients, the harvesting rate increased to 
61%. This was accomplished by modifying our techniques to include ringing out 
sponges, keeping the suction tip at an angle and always in the wound, and the 
suction kept as low as possible. Our average total blood loss per case has 
continued to decrease after employing the electrocautery device almost 
exclusively in order to perform the surgical procedures. The scalpel was only 
used to make the initial skin incision. Spinal anesthesia was employed whenever 
possible and hypotension was used in 83% of the cases} the systemic blood 
pressure was maintained at 80 plus or minus 5 mmHg. Of the first group of 
patients, only six required supplemental homologous transfusions in the post-
operative period. In the next 131 cases, only two patients needed supplemental 
homologous transfusions. It is interesting to note that as our techniques of 
minimizing blood loss improved, the cell saver was used only as a standby 
modality in over 52% of the patients. Since the amount recovered during the 
surgical procedure was so small, it was hardly worthwhile reinfusing the 
harvested blood back to the patient. The experience obtained in other surgical 
specialities using this method, and the cell saver, have paralleled the reported 
orthopaedic experience. Only one case of hepatitis was reported where the cell 
saver or the ATS-100 were used exclusively. 
Table V: Intraoperative Auwlogow Transfusion in 43 Spinal Fusions 
EBL 
(Estimated Cell Saver 
Name Operation blood loss) (Recovery) Pre-Op H & H Post-Op H & H 
T.B. Antenor spinal fusion with Zilke inst. 800 cc. 350 cc. 14.0/40.3 13.4/39.7 
Tll-L5 
K.M. Posterior spinal fusion with H.I. T5-L3; 700 cc. 250 cc. 12.9138.4 12.5/34.8 
n. posterior iliac crest bone graft 
E.T. Posterior spinal fusion with H.L Tli-L4 No data No data 12.2/36.0 11.6/33.1 
rt. iliac crest bone graft - single 
distraction rod 
C.P. Posterior spinal fusion with Harrington 800 cc. 250 cc. 16.7148.0 16.6/48.0 
inst. 
A.B. Posterior spinal fusion with Harrington 900 cc. 600 cc. 13.6142.6 13.5/42.3 
inst. T2-12 
J.D. Posterior spinal fusion with Harrington 500 cc. 300 cc. 14.2141.8 13.5140.2 
inst. 
S.M. Posterior spinal fusion.with Haningwn 800 cc. 250 cc. I 1.7/34.5 11.6132.6 
mst. 
J.T. Posterior spinal fusion with HaHington 750 cc 300 cc. 13.6139.4 15.8/45.9 
mst. 
A.S. Posterior spinal fusion with Harrington 650 cc. 250 cc. 13.6138.4 12.7/36.6 
in st. 
D.Z. Posterior spinal fusion with Harrington 500 cc. 250 cc. No data 14.1/42.2 
inst. 
LF. Posterior spinal fusion with Harrington 900 cc. 500 cc. plus 11.8135.4 11.1132.9 
inst. 1 unit bank 
blood 
D.G. Posterior spinal fusion with Hanington 400 cc. 250 cc. 12.9/38.2 12.1/36.2 
mst. 
K.A. Posterior spinal fusion with Harrington 450 cc. 150 cc. 14.2142.6 13.1138.8 
inst. 
V.D. Posterior spinal fusion with Harnngton 1100 cc. 500 cc. 13.8141.4 13.2/40.0 
mst. 
M.S. Posterior spmal fusion with Harringwn 600 cc. 300 cc. 13.6/40.4 12.5137.9 
mst. 
C.B Posterior spinal fusion with H.I. 375 cc. 175 cc. 1.2.8/38.6 12.7/38.4 
Tl0-L4; n. iliac crest bone graft 
w.c. Posterior spinal fusion with H.l.- bone 600 cc. 300 cc. 13.1137.7 12.6137.1 
graft - T3-ll 
D. G. Posterior spinal fusion transverse 500 cc. 250 cc. plus 11.6/33.9 12.3/38.4 
process to transverse process I unit packed 
bilat., L2-3-4 cells (bank) 
T.B. Posterior spinal fusion with H.L 1200 cc. 500 cc 14.2/42.4 13.3/38.8 
T3-Ll with single Harrington 
distraction rod. Rt. posterior iliac 
bone graft 
K.W Posterior spinal fusion T5-L2 with 800 cc. 300 cc plus 13.0139.2 14.2142.8 
autogenous bone graft & application 1 unit whole 
of transverse tX bank blood 
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Table v (contd): Intraoperative Autologous Transfusion in 43 Spinal Fusions 
EBL 
(Estimated CeU Saver 
Name OpertUian blood loss) (Recovery) Pre-Op H & H Post-Op H & H 
M.P. Posterior spinal fusion with Knoch rod 1000 cc. 500 cc. 14.6/43.0 14.6141.2 
C.H. Posterior spinal fusion with H.I. T3-L4, 650 cc. 300 cc. 13.0/40.0 11.9/35.5 
distraction rod #1253 & 1254 hooks 
direct trans. tx. T7-9 n.; Knodt direa 
trans. tx. L2-3 rt. posterior iliac bone 
graft 
s.w. Posterior spinal fusion with H.L T4-Ll 600 cc. 250 cc. 13.4138.3 13.!/37.6 
with direct trans. tx. T7-9 
C.K. Posterior spinal fusion with autogenous 800 cc 300 cc. 14,1/40.2 12.2/36.1 
bone graft from tt. i!iac crest, Tl2-L5 
K.H. Posterior spina! fusion with H.L and 900 cc. 400 cc. 12.4/35.1 13.1/39.1 
trans. tx.; T5-L4 with autogenous 
bone graft correction of thoracic 
and lumbar curve: 
P.D. Posterior spinal fusion with Harrington 500 cc. 350 CC. 12:8137.9 l !.6/34.4 
inst. 
R.M. Posterior spinal fusion with Harrington 1300 cc 450 cc. 15.4/45.3 14.7/43.9 
inst. 
Lf. Posterior spinal fusion with Harrington 800 cc. 500 cc. 13.8140.0 12.0/39.7 
inst. 
M.M. Posterior spinal fusion T4-L4: direct 1400 cc. 225 cc. c.s. 13.5/38.0 15.4146.8 
trans. tx. T7 -9 whole blood 
1000 cc. 
R.O. Posterior spinal fusion with Harrington 850 cc. 600 cc. 13.7141.6 12.9/38.4 
mst. 
H.R. Posterior spinal fusion wi~h Harrington 800 cc. 350 cc. 14.5143.9 13.0/38.5 
mst. 
A.F. Posterior spinal fusion with Harrington 800 cc. 350 cc. 11.8/34.3 10.4/30.8 
inst. 
W.J. Posterior spinal fusion with Harrington 700 cc. 300 cc. 15.0146.9 14.2/43.0 
inst. 
C.D. Posterior spinal fusion with Harrington 225 cc. 150 cc. 13.8139.8 11.4/34.0 
inst. 
S.P. Posterior spinal fusion with Harrington 1000 cc. 500 cc. 14.3/42.8 12.6/35.9 
mst. 
D.B. Posterior spinal fusion with Harrington 700 cc. 350 cc. 13.3139.0 10.9/32.0 
insL 
B.N. Posterior spinal fusion with Harrington 150 cc. 80 cc. 14.7/43.4 13.8139.9 
in st. 
P.M. Posterior spinal fusion with Harrington 3500 cc. 1250 C.S. plus 15.6146.3 14.4/43.1 
inst.; tram. o::. and laminectomy 2000 cc. whole 
ofL4 blood 
T.M. Posterior spinal fusion with H.I.: 250 cc. 100 cc. 13.0/38.0 11.9/35.3 
laminectomy of T9 & 10 
D.R. Poscerior spinal fusion with H.L T4-L2 1000 cc. 250 c.s. 13.7/39.9 12.5/37.0 
2 units whole 
blood 
M.W. Posterior fusion, Cl-2 250 cc. 100 cc. 14.1/41.9 13.8/41.6 
S.L. Posterior spinal fusion with Harrington 1500 cc. 500 cc. 14.1/40.0 12.6/35.0 
inst 
A.B. Posterior spinal fusion wich H.l. T8-L4 800 cc. 300 cc. 13.8/39.5 13.1137.5 
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Tab 1 e V ( contd): Intraoperative Autologous Transfusion in 17 Lumbar Laminectomies 
EBL 
(Estimated Cell Saver 
Name Operation blood loss) (Recovery) Pre-Op H & H Post-Op H & H 
B.A. Lumbar laminecwmv 200 cc. 125 cc. 14.6143.0 12.1135.2 
Gill procedure. posterior lateral 
spinal fusion n. iliac crest 
R.S. Complete laminectomv 2000 cc. 750 cc. I5.3145.0 !3.8141.4 
L4 lateral transverse process fusion 
K.G. Lumbar laminectomY 500 cc. 300 cc. plus 12.1137.5 13.9/41.9 
l unit W.B. 
bank 
J.B. Lumbar lammenomv 400 cc. 250 cc. !5.2/47.0 13.2/37.5 
with spinal fusion L5-S 1 
D.C. Lumbar laminectomy 300 cc. 150 cc 14.3142.6 ll.l/32.1 
L5-Sl bilat. with fusion transverse 
process L5-S2 
D.L. Lumbar laminectomy with biopsy, L4-5 600 cc. 300 cc. 14.7/44.6 13.7142.2 
disc and vertebral body 
J.D. Lumbar laminecwmv 500 cc. 250 cc. 17.1147.3 12.2/35.0 
post. and late fusion L4-S I 
E.Y. Lumbar laminecwmv LS 600 cc. 200 cc. 12.7!38.0 11.5/34.5 
D.W. Lumbar laminectomv with P.S.F. LS-51 700 cc. 250 cc. 16.3146.8 I L6/34.0 
P.C. Lumbar laminet:tomv with P.S.F. 200 cc. 100 cc. 11.6/34.2 :\o data 
W.E. Lumbar laminectomv 600 cc. 350 cc. 13.8/40.5 I l.l/32.8 
C.P. Lumbar laminenomy with P.S.F. L4-Sl 500 cc. 250 cc. 13.5140.9 Two davs P.O. 
9.5/27.7 
E.T. Lumbar laminenomv wirh Weiss spring 250 cc. 125 cc. 12.3/36.0 ll.0/32.7 
E.P. Lumbar laminectomv 300 cc. ISO cc. 11.7134.2 9.6128.3 
D.B. Lumbar laminectomv with Knodt rods 1000 cc. 500 cc 15.7144.2 !1.6/32.4 
L4-Sl 
T.S. Lumbar lammectomv, bilat. LS-51 400 cc. l 00 cc. 15.7/44.8 14.4/40.6 
\LS. Lumbar laminectomy, bilat. 400 cc 200 cc. 10.9/31.5 9.6128.9 
Nue rod and foraminowmy 
Intraoperative Autologous Transfusion in 22 Total Hip Replacements 
EBL 
(Estimated Cell Saver 
Name Operation blood loss) (Recovery) Pre-Op H & H Post-Op H & H 
LB. R<. total hip replacement 250 cc. 100 cc. 12.9/37.5 13.1/40.0 0.5. R<. total hip replacement 200 cc. 100 cc. 12.9/37.9 12.8/38.8 E.C R<. total hip replacement 200 cc. 100 cc. 9.2127.1 8.7/25.4 
L.P. L<. total hip replacement 400 cc. No data 1 1.3/35.3 9.5/28.7 
P.B. L<. total hip replacement 400 cc. No data I 1.8/34.8 7.6/21.9 
A.R R<. total hip replacement 400 cc. No data I 0.9/32.0 10.6/32.0 K.R. L< total hip replacement No data No data 13.3140.0 12.6/35.7 !Vi.A. Total hip replacement 600 cc. 300 cc. 11.8135.4 11.3/34.1 T.H. Lt. total hip replacement 800 cc. 250 cc. I 5.9/49.2 14.9145.2 
W.H. Rt. total hip replacement 500 cc. 200 C(. 14.9/44.3 12.0136.8 C.T. Rr. total hip replacement 300 cc. No data 13.9/39.0 I 1.9/33.9 J.M. Lt. total hip replacement 500 cc. 250 cc. 13.5/40.5 12.8/38.4 
R.P. L<. total hip replacement 500 cc. 200 cc. 14.9/44.1 13.4/39.5 G. H. R< wtal hip replacement 1000 cc. 350 cc. with 10.9131.7 13.1/39.5 
1 unit whole 
blood 
R.R. ., total hip replacement 700 cc. 300 cc 16.0/48.2 15.7/47.6 J.D. L<. total hip replacement 500 cc. 200 cc. 15.0144.0 14.4/42.6 V.K. .,. total hip replacertJent (revision) 600 cc. 200 cc. 1 1.5/33.9 12.0/37.6 
R.L. Lt. total hip replacement 200 cc. 100 cc. 13.8/42.3 11.3/33.2 G.M. Lt. total hip replacement 300 cc. !50 ((. 11.3133.9 9.9132.5 C.H. Rt. lOtal hip replacement 200 cc. 100 cc. 14.9/43.1 12.3/38.5 W.T. Lt. total hip replacement 500 cc. 250 cc 10.2/29.6 7.4/22.5 R.S Rt. total hip replacement No data No data 12.7/35.8 12.3/36.6 
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Discussion 
Intraoperative 
who, in 1874, 
after being 
reinfusion as a viable concept should be credited to Highmore 
suggested that the patient's own blood could be given back to him 
defibrinated and warmed. He proposed that the method of 
administration wou1d be via a Higginson 1 s 
Nonoperative autotransfusion was advocated 
syringe and a transfusing pipe. 
originally, however, by Blundell 
(1818), when he used the technique in severe postpartum hemorrhage patients. In 
1885, Duncan, using phosphate of soda as an anticoagulant, salvaged 100 cc of 
whole blood during a surgical amputation of a leg and reinfused it into the 
patient who apparently did not suffer any ill effects. Encouraged by his first 
triumph with this technique, Duncan continued to use it on several other 
patients, although he did not report it. In 1914, Ties reported his experience 
in the treatment of ectopic pregnancies. By 1922, a total of 164 cases of 
intraoperative rei nfusi ons were accumulated and analyzed by Burch. The first 
report of employing this technique in the United States came in 1931 when 
Lockwood used it in performing a splenectomy for Banti 1 5 syndrome. Since that 
first American literature report, the technique has been used in the treatment of 
hemothorax, ruptured spleens, carbon monoxide intoxication, amputations, ectopic 
pregnancies, abdominal wounds, stab \Vounds of the heart, neurological and 
orthopaedic procedures, multiple trauma, and chest and cardiac surgery. 
In 1970, Klebanoff, who two years earlier introduced the disposable 
autotransfusion unit (made by Bentley), reported that in over 1,000 cases of 
documented autotransfusions in the Western literature not a single death was 
directly attributed to 
standardization of this 
reinfused. It was only 
the autotransfusion itself. There was, however, no 
method by which the blood was collected, processed, and 
with the emergence of high quality medical plastics and 
improved medical engineering that it was possible to develop a high quality and 
reasonably reliable unit to perform such a task with uniformed results. 
In the late 1960's, for many various reasons, the demand for homologous blood 
increased sharply. Among them were the large number of Vietnam war injuries, the 
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rapid advancement in thoracic and open heart surgeries, and the development of 
the rapid emergency transport system. This has resulted in an increased demand 
for large quantities of blood for trauma cases, as well as for patients for 
elective surgery. Despite the enormous growing need for blood, the availability 
of it was drastically cut when the use of paid donors was curtailed and better 
screening methods eliminated diseased donor's blood. To compound the problem, 
federal and state laws regarding blood transport became considerably more 
restricted. The shortage of blood has again reintroduced the concept of 
autotransfusion. 
In 1968, the Bentley (ATS-100 device) became the first commercially available 
autotransfusion apparatus to appear on the American market. It was the first 
attempt in adapting a variable speed roller pump and a cardiotomy reservoir with 
a filter of nylon mass, two being for suction lines and reinfusion lines, as well 
as a suction device. Today an alarm system that monitors the blood level in the 
reservoir is also available in order to prevent the potential development of air 
embolisms. Utilizing this device, all sequestered blood that is not grossly 
contaminated can be aspirated and reinfused at a rate which is only limited by 
the size of two venous catheters that provide a portal of entry into the 
patient's vascular system. Before using the ATS-100, the patient must be 
completely heparinized using 300 units/kg of body weight. Even though it has 
been implicated in causing fatal air emboli, this complication can be avoided by 
the use of a trained technician and an alarm system. This device can be quickly 
set up and is particularly useful in cases where blood loss is rapid. The blood 
is returned back into the patient in a filtered, but otherwise unaltered, state. 
This fact is an important one especially when large amounts of blood are lost and 
clotting factors may not be readily available for replacements. The author has 
used this technique on 47 patients without complications. 
In the late 1970's, the cell saver apparatus (manufactured by the Heonetic 
Corporation) became widely used and popular. It works in the following manner: 
the blood is aspirated from the surgical field via a suction tip left always at 
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the operating site. It goes into a double lumen heparin washed tube after 
passing through a filter. The blood is then pumped into a holding reservoir. 
Fat tissue particles, platelets, and white cells are filtered out; 1,000 cc of 
normal saline is used to wash the filtrate which is pushed into a centrifuge by a 
roller type pump. Plasma, myoglobin, heparin, free hemoglobin, and clotting 
factors are removed. The washed red cells are packed and given back to the 
patient. The author has been able to return approximately 61% of the shed red 
cells back to the patient by employing low suction and meticulous techniques. No 
changes in ProTime, PTT, 23 DPG 1 5 and other tests which have been performed were 
observed. Seven hundred and fifty eight patients over the past four years have 
been successfully treated by the author with this apparatus. Three hundred and 
seventy-tour were cardiac cases, three hundred and thirty-one orthopaedic cases 
and fifty-three were 
orthopaedic group will 
deaths in this group 
classified in the general surgery category. Part of the 
be discussed in detail later on In this chapter. No 
of patients were directly attributable to the use of the 
cell saver. When using this apparatus, one has to monitor the patient 1 S state of 
hydration very carefully because he may have a normal hematocrit, but still be 
hypovolemic. Unlike the ATS-100, the cell saver is thought to be easier to 
operate, less versati1e, and requiring more colloidal support. To be cost 
effective, the average minimum of units of blood needed to be reinfused are 4.5 
for the Bentley and 3.7 for the cell saver. A report from Massachusetts General 
Hospital (1981) suggested that the net saving per operation, per patient was $115 
with the Bentley and $176 with the cell saver. 
Some degree of cell damage is Inflicted by both devices in the process of 
harvesting the cells. With the Bentley, one can observe a rise in plasma free 
hemoglobin, which is probably due to the suction roller pump compression 
interface with air and tissue, as well as turbulence in the tubing reservoir and 
filters. The cell saver gives a much lower level of plasma free hemoglobin, 
which Is due to the washing. Stillman (1980) has shown that protection against 
red cell damage can be achieved in dogs by the use of methylprednisolone. 
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Hemoglobinuria, per se, does not diminish renal function which is more influenced 
by hypotension, acidosis and hypovolemia. 
A major concern in the past has been the possible detrimental effect of the 
ATS-100 on coagulation mechanisms and the possibility of initiating disseminated 
intravascular coagulopathy. It is, however, difficult to point the finger at 
this system because most ATS patients, as reported by other investigators, have 
received large amounts of homologous blood as well as having superimposed insults 
of severe tissue trauma, shock and acidosis. Platelet aggregation has caused 
some reduction in platelet count, but this has not been clinically significant. 
Decrease in fibrinogen levels and increase in ProTime and PTT time can occur 
which reflects some loss of clotting factor, dilutional effects and systemic 
heparinization which is often incompletely reversed at the end of the operation. 
The cell saver avoids reinfusion of activated clotting factors but at the expense 
of washing out other factors in the discarded plasma. 
The optimal anticoagulation which prevents microemboli and potentially 
disastrous respiratory failure seems to be systemic heparinization and the 
addition of ACD or CTD to the suction system. 
Even though Klebanoff demonstrated in 1970 
caul d be safely rei nfused into dogs without 
that grossly contaminated blood 
ill effects, there has been a 
continued reluctance 
contarni nated by bowel 
blood using the cell 
on the part 
content. We 
saver and 
of surgeons to reinfuse blood which has been 
found it necessary to reinfuse contaminated 
observed few, if any, problems - Sepsis is 
obviously easier to treat than rigor mortis. Broad spectrum antibiotics regimen 
is given to all such patients. 
For the sake of completeness it is only fair to mention that a similar cell 
washing device, manufactured by IGM, and utilizing a Sorenson 1 s collection system 
is also on the market today. We have had no personal experience with this 
apparatus, but, regarding its use in the intraoperative reinfusion, it has been 
observed that it is a rather large, not easily movable, piece of equipment, and 
that a collection systern must, therefore, leave the room for a washing process. 
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When this machine is used in a busy operating room, delays and potential fatal 
complications can occur through clerical errors. 
The Jehovah's Witness patient 1 S view on the use of intraoperative auto-
transfusion is uniform in the objections to the storage element of the process, 
no matter how short the period of time. Yet, there is always an element of 
storage in any extracorporeal circulatory device and that must always be 
explained to the patients. Some have accepted this method as a conscious matter, 
while others have rejected it. We have had a number of patients who refused to 
undergo cardiac surgery because they could not accept the concept of their blood 
circulating through a pump oxygenator. As a general policy, we have never tried 
to change the religious view points of this group of people, but rather work to 
improve and modify the available hardware to mi nirnize storage time and to keep 
blood constantly circulating. 
There is no question that homologous blood has many disadvantages. It is 
expensive, not always available~ and overly utilized. It can cause febrile 
reaction, isoimmunization, syphillis, malaria, bacterial infection, Epstein-Barr 
virus, Australian antigen positive 
major histocompatibility reaction, 
average unit of blood sitting on 
virus, negative hepatitis producing virus, 
vascular overload, and hemosiderosis. The 
the shelf in the blood bank has a high 
concentration of potassium, ammonia and hydrogen ions in the plasma. The red 
cells are low in 23 DPG. Also larger than normal accumulation of cellular debris 
is found in stored blood. 
Blood conservation efforts along many fronts, of which intraoperative 
reinfusion is only a part, will help our dependency on the blood bank and assure 
that blood is available to the people who want it >~hen it is needed. If we can 
only continue to remind ourselves that the best blood we can give a patient is 
his own, and that transfusing a patient with a unit of whole blood is analogous 
to 
we 
giving 
begin 
a 
to 
patient 
1 oak at 
a unit of liquid organ transplant. Then and only then will 
the patient as being his own blood bank and treat him as 
such. Transfusing an anemic asymptomatic patient makes the doctor feel 
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better and the medical chart look good in an audit situation, but the patient is 
subjected to needless, extensive, and potentially hazardous treatment. 
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IV-ii The use of intravenous iron dextran 
The intravenous use of iron dextran has been recognised by a number of 
research clinicians to be a viable therapeutic option in the treatment of iron 
deficiency anemias in the Jehovah's Witness patient who steadfastly refuses the 
alternative of blood transfusions in order to correct his acquired anemia. The 
use of intravenous Imferon and Folic Acid coupled with intramuscular injections 
of 8-12 and nandrelone decanoate, and at times, when indicated) intravenous 
hyperalimentation has become a life saving reality. It is our purpose in this 
report to outline our clinical results with Jehovah's Witness patients who 
received intravenous iron dextran in the past nine years. 
Eight hundred and forty one Jehovah's Witness patients ranging in age from 11 
years to 89 years received intravenous iron dextran, and Folic Acid therapy, as 
well as intramuscular injections of B-12 and Deca-DUI'Obolin, for the purpose of 
correcting iron deficiency anemia. This study began in 1974 and, to date, is 
continuing as part of an ongoing treatment modality for anemic Jehovah 1 S Witness 
patients. The amount of Imferon needed was calculated from the formula - total 
dose of iron to be administrated = 3 x weight in pounds of the patient x the 
deficit in hemoglobin. Another formula which can be used is: 
0.3 x body weight x (100 Hb x 100) = mgm iron 
One half cc of Imferon was given as an intravenous test dose over a five minute 
period during which vital signs were carefully monitored; when no adverse 
reactions were noted, the remaining amount of Imferon was given over a two to 
three hour period diluted in 1,000 cc of normal saline; the maximum amount given 
to a single patient was 105 ml. 
Six to eight mg of Folic acid was given intravenously every day until either 
the patient left the hospital, or intravenous therapy was no longer needed. 
Intramuscular injection of a single dose of 300 mg of Deca-Durobolin was given as 
a single treatment, 2 cc of Vitamin B-12 were likewise given intramuscularly 
initially and repeated four times every other day on each patient. Intravenous 
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hyperalimentation was administered when judged appropriate. Folic acid assays 
showed that the measured blood levels in those patients had been generally low. 
CBS and reticulocyte counts were obtained daily. The most frequent causes of 
anemia were gastrointestinal and vaginal bleeding, malignancy, surgery, and 
trauma. The hemoglobin levels of the patients included in this study ranged from 
1.6 gms to 9.2 gms per 100 ml of blood. 208 patients had a hemoglobin below 5 
gms. 
No appreciable change in the hemoglobin concentration was noted for the first 
twenty-four hours, after which the hemoglobin concentration rose at an average 
rate of 0.41 gms ( + 0,3 SD) per day. Younger patients with hemoglobin 1 evel s 
below 5 gms per 100 ml and who were suffering from malignant diseases showed the 
greatest improvement in this series, while older, debilitated patients with 
advanced cancer and renal problems showed the least improvement. In some cases 
the debilitated group of patients increased their hemoglobn production follo>~ing 
supplementary addition of hyperalimentation - standard total parenteral nutrition 
providing 1 calorie per cc. 
Patients with known severe drug allergies, severe asthma, advanced rheumatoid 
arthritis, and other auto-immune diseases were excluded from this study. Twelve 
patients developed mild and transient reactions including superficial phlebitis, 
fever (less than 100'F), rash and myalgia. No respiratory complications were 
noted and no anaphylactoid reactions were seen. There was no mortality. In 33 of 
these patients intra-operative liver biopsies were performed at various intervals 
following the iron therapy as part of a follow-up; these liver biopsies were not 
performed as a separate scheduled procedure, but incidently performed during 
elective or emergency operations subsequently performed on these patients. No 
liver dysfunction or hemosiderosis was noted in any of these patients. 
Intravenous administration of lmferon is the most effective way of restoring 
depleted iron stores in man. The intramuscular route is painful and the product 
stains the skin, binds to muscle, and has been shown to cause fibromyosits~ as 
well as soft tissue sarcomas at the site of the injections. Iron is absorbed 
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more slowly with much less uniformity after intramuscular administration when 
compared with the intravenous option. The oral administration of iron is poorly 
tolerated by the severely anemic and debi 1 i tated patient and especially in those 
suffering from various degrees of ileus, intestinal obstruction, colitis, 
malabsorption syndromes, 
diseases. The dark colour 
gastritis, peptic ulcers, and inflammatory bowel 
of the stool often alarms the Jehovah's Witness 
patient needlessly since they tend to confuse this alteration in color with 
melena. In 1973, the Food and Drug Administration approved the use of 
intravenous lmferon, and thus, opened the door for the option of using total dose 
infusion as an alternative to blood transfusons in the Jehovah's Witness patient. 
Adverse reports in the 1 i terature re1 ati ng to the intravenous total dose 
infusion have been sporadically reported. They included reports of arthralgia, 
myalgia, fever, rash, thrombophl ebi tis, pulmonary emboli~ headaches, asthma, 
wheezing, and occasionally respiratory arrests. These reports have heightened 
the level of concern among physicians and limited the use of this therapy in the 
U.S.A. Our experience has demonstrated that, by excluding the patients with 
known severe drug related allergies, asthma, rheumatoid arthritis and other 
auto-immune diseases from this treatment plan, this modality becomes an extremely 
reasonable approach for rapidly correcting anemia without the use of blood 
transfusions 
Hemotherapy has been reported to cause hepatitis, febri 1 e reaction, genetic 
sensitization, disseminated intravascular coagulopathy, microenboli, and has been 
implicated in the transmission of malaria and syphilis. This type of therapy 
carries a greater risk than does the intravenous use of iron dextran. In a 
collected series of over 2,000 patients receiving Imferon, Wallerstein (1968) 
showed that only 1 to 2% of the patients developed a reaction to this therapeutic 
modality. 
We feel that the use of normal saline as a diluent to iron dextran has 
greatly contributed to the reduction of incidents of allergic reactions and 
phlebitis reported by other investigators using Dextrose and Dextran. Some 
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physicians have been administrating undiluted Imferon to their patients, though 
we do not recommend it. 
The intravenously administered iron is picked up by the reticuloendothelial 
system and the liver. The body's capacity to store iron is variable. We have 
had the opportunity of performing liver biopsies on patients who have received 
Imferon at various intervals following the treatment and found no evidence of 
liver dysfunction or hemosiderosis. After administering 3.000 mgs intravenously, 
Wallerstein (1968) discovered that serum iron decreased linearly at a rate of 525 
micrograms per hour. Five weeks following administration, serum iron levels were 
recorded at 40 micrograms per 100 ml. 
The addition of Folic Acid, Vitamin B-12, Deca-Durobolin and 
hyperalimentation when appropriate, has greatly improved the rate of hemoglobin 
production in the severely anemic patient and certainly provides the necessary 
stimuli, as well as the building blocks for an accelerated hematopoietic 
response. 
We can only hope that further intensive clinical and laboratory research will 
add to the scientific data available to date, as well as improve on the safety 
aspect of total dose infusion of Imferon, to make it a significant entity in the 
treatment of iron deficiency anemia. We are also anxiously waiting to see the 
data on work performed by some investigators on the role of erythropoietin in 
raising hemoglobin levels in anemic patients. We certainly hope that this 
substance can be incorporated in the future to the treatment plan which we have 
de;cribed above and that this will improve on our results. 
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CHAPTER V 
FLUOROCARBONS 
V-i Introduction 
V-i-1 Historical Evolution of the use of perfluorochemicals as blood substitutes 
The idea that perfluorocompounds may act as oxygen carriers to sustain life 
may have started from the communication of Kylstra (1962) of 'mice as fish', when 
he showed that mice could be kept alive when immersed in hyperbaric solutions of 
oxygen in aqueous saline solutions. Howlett (1965) used perfluorocompounds as 
blood oxygenators, while Clark and Gollan (1966) demonstrated the high oxygen 
solubility of perfluorochemicals (PFCs) by submerging mice in its liquid for 
extended periods. Their animals were able to obtain sufficient oxygen by 
breathing the liquid and, upon removal, showed no apparent ill effects from the 
experience. The authors also showed that breathing such liquids can protect mice 
from the effects of rapid decompression and he suggested that the liquids would 
be useful for such applications as escape from submarines and deep-sea diving. 
As also shown by Clark and Gollan, oxygen is highly soluble in liquid PFCs. 
Whereas normal saline or blood plasma dissolves about 3 percent oxygen (by 
volume) and whole blood with a normal haemoglobin concentration contains about 20 
volume percent, pure PFCs dissolve 40 percent or more. Carbon dioxide is at least 
twice as soluble. The solubility of oxygen in water, some nonpolar liquids and 
PFCs are shown in Tables VI and VII. 
Clark and Gollan (1966) were the first to attempt to use perfluorochemicals, 
instead of blood, to supply an organ with oxygen when they showed that an 
isolated heart of a rat would continue to contract vigorously when perfused with 
a perfluorocompound saturated with oxygen. 
Preliminary experiments with emulsions of PFCs have shown much promise. 
Sloviter and Kamimoto (1967) have shown, for example, that isolated rat brains 
Table VI: Solubility of oxygen and carbon dioxide in PFCs 
Compound 
Perfluorotetrahydrofuran 
Perfluorotributylamine (FC-43) 
Perfluorotetrahydrofuran 
Perfl uorotri butylamine 
Perfluorooctane (CSF18) 
Freon E3 
Freon E4 
Perfluorodecalin (FDC) 
Perfluoromethyldecalin 
*Solubility in liquid PFCs 
Temp. 
oc 
25 
37 
25 
37 
25 
37 
25 
37 
37 
37 
37 
37 
37 
37 
37 
02 
(ml /lOOml )* 
12.6 (air) 
11.7 (air) 
48.8 
48.5 
10.3 (air) 
10.4 (air) 
38.9 
40.3 
(Vol %)** 
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41 
48 
56 
36 
45 
42 
**Solubility in PFCs as dispersion stabilized with Pluronic F-68 
Sol ubi 1 ity 
C02 
(ml /100ml )* 
-
-
192.0 
160.0 
152.0 
142.0 
(Vol %)** 
147 
108 
180 
43 
77 
134 
126 
N2 
(ml/100ml )* 
27 .9 (air) 
26.7 (air) 
33.4 
34.0 
22.8 (air) 
21.6 (air) 
28.4 
28.6 
(Geyer 1975) 
"' 0 
Table VII: Solubility of oxygen in water, silicone, and organic liquids 
Liquid 
Acetone 
Benzene 
Carbon Tetrachloride 
Ethyl Alcohol 
Ethyl Ether 
Silicone (20 cs) 
Water 
*Values for 25°C 
Solubility of Oxygen* (ml/100 ml) 
28.0 
22.5 
30.3 
24.2 
44.7 
18.3 
2.9 
(Geyer-1975) 
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perfused with such emulsions retain their activity as well as, or better than 
they do when 
results using 
and 
be 
kidneys, 
frogs can 
demonstrated 
Fx-80, could 
perfused with a suspension of erythrocytes. They obtained similar 
the ernul si ons to maintain nonnal function in isola ted canine 
have also shown that a substantial portion of the blood of mice and 
replaced by such an emulsion with no apparent ill effects. It was 
that mice, whose blood contained 10 to 20 percent of emulsified 
survive for a considerably longer time than controls in an 
atmosphere containing 4% carbon monoxide. 
Geyer et al. (1968) have successfully replaced all of the blood of rats with 
a PFC emulsion. These animals showed no apparent ill effects from infusion of the 
blood substitute and immediately began producing erythrocytes and blood proteins. 
By the time most of the PFC had been cleared from circulation (generally within 
about a week) the animals had generated nearly all their erythrocytes. Moreover, 
they had a normal life-span after the replacement. This success, depended on the 
development of the proper flow characteristics of the emulsion, particularly a 
reduction in its viscosity, and was the result of five years' work in refining 
the preparations. 
Intravenously injected PFCs can be lethal because they are immiscible with 
blood and can thus produce embolic phenomena. This problem is overcome by 
dispersing the PFC into very small particles with the aid of a surfactant. In 
1968, Geyer made the fortuitous discovery that members of a family of poly-
oxyethylene-polyoxypropylene polymers called Pluronics not only emulsify the 
organic phase, but also serve as plasma expanders to reproduce the oncotic 
pressure normally provided by blood proteins. A typical preparation, then, would 
contain about 15 to 30 percent PFC by weight and 2.5 to 10 percent surfactant in 
an aqueous solution with an ionic composition resembling that of blood. 
Clark (1970) has replaced as much as 90% of the blood of dogs with these 
emulsions, and has observed no ill effects; some of these dogs were kept alive 
longer than 4 years after the replacement. Using an oxygen electrode implanted 
in the brain of these dogs, he has shown that the partial pressure of oxygen in 
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the bloodstream is at least three times as high under conditions of 90% 
replacement as it is in control animals. The pressure is also well above that at 
which the remaining hemoglobin releases oxygen, i ndi cati ng that all oxygen 
transport is provided by the ernul si on. 
The emulsifying agents most used in preparing PFC dispersions have been egg 
and soybean phospholipids, bovine albumin and especially Pluronic F-68 as 
mentioned above. The last has played, and continues to play, a crucial role in 
the field of PFC artificial blood as Geyer (1975) emphasizes in his excellent 
review. 
Pl uroni c, 
The Pluronic polyols are nontoxic at low concentrations. For a typical 
the LD50 is more than 10 grams per kilogram of bodyweight and, unlike 
all ionic and many non-ionic surfactants does not cause hemolysis of 
erythrocytes. 
Fluronic F-68, 
surfactant and 
which has a mean molecular weight 
detergent. It has been used as an 
of 8,350 is a non-ionic 
emulsifying, dispersing, 
wetting and defoami ng · agent. Recent 
demonstrated that Pluronic F-68 may 
clinical and experimental studies have 
alleviate some of the adverse effects of 
extracorporeal circulation. Pluroni.c F-68, when added to the circulating blood 
in a final concentration of 0.6 mg/ml, has been reported to reduce fat 
embolization (Adams et al. 1959; Danielson et al. 1970; Miyauchi et al. 1966; 
Wright et al. 1963), hemolysis (Miyauchi et al. 1966; Paton et al. 1968; Sloviter 
and Kamimoto 1967), and sl udgi ng (Geyer 1973; Grover et al. 1969) as well as to 
lower viscosity without changing the hematocrit. These investigators have 
accepted the use of Pluronic F-68 as an additive for extracorporeal circulation 
and to allow it in the whole circulation of humans. 
It has been shown that perfl uorotri butylamine (FC-43), ernul sifi ed with 
Pluronic F-68, is quite stable and endures repeated circulation through a hollow-
fiber dialyzer and heart-lung machine with bubbling oxygen. This suggests the 
possibility of using it for continuous perfusion of the isolated kidney. Most 
investigators, who have used Pluronic F-68 in PFC artificial blood formulations, 
have not recorded any ill effects from this agent (Geyer 1975; Yokoyama et al. 
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1975; Clark et al. 1975; Rosenblum 1975; Geyer 1970). It is known that Pluronic 
F-68 precipitates plasma protein in vitro, and in vivo, at a concentration of 20 
mg/ml or more (Rose 1966). This polyol is, however, very rapidly excreted from 
the circulation via the urinary path (90% or more elimination in 3 hours after 
intravenous injection of 2g/kg body weight of rabbit, (Okamoto 1975)) and is not 
retained in body tissues. In addition, the in vivo precipitation of plasma 
protein does not occur at 38oC when the concentration of Pluronic F-68 is 8% or 
lower - this corresponds to an intravenous injection of 3 gm/kg body weight. 
Geyer (1975) opines that it would seem unwise to eliminate this useful compound 
until adverse results are observed. 
Pluronic F-68 is not capable of emulsifying all types of PFC compounds. For 
example, Freons El and E2 can be emulsified into fine form, but coarse particles 
occur within a short time and it has not been possible to prepare absolutely 
stable emulsions of perfluorodecalin (FDC) with Pluronic F-68. A number of PFCs 
have been tested for emulsion stability as summarized in Table VIII by Geyer 
(1975). 
Because of the excellent stability and ready availability of the emulsifiers, 
FC-43/Pluronic F-68 emulsion was selected as the most suitable for use in animal 
experiments (Geyer 1970; Geyer 1975; Yokoyama et al. 1975; Clark et al. 1975; 
Rosenblum 1975). In 1973, Geyer showed that his 'bloodless rats', whose blood 
has been totally replaced by FC-47, survived the replacement and in 10 days the 
plasma protein and hematocrit levels were back to normal. The animals continued 
to grow and develop normally. It should to be noted, however, that FC-43 in the 
emulsion is retained in the liver, spleen and other organ tissues for long 
peri ads of time. 
Apart from Pluronic F-68, purified yolk phospholipids are known to be safe 
emulsifying agents, that are, moreover, easily metabolized in the body. Soybean-
oil emulsified with yolk phospholipids (lntralipid) was developed by Wretland 
(1972) and has been widely used since 1968 for intravenous nutrition in over a 
million cases with no confirmed report of untoward reactions. If this substance 
Table VIII: Some PFCs used in artificial blood and stability of their emulsions 
stabilized with Pluronic F-68 
Compounds Emulsion Stability 
Perfl uorotri butylamine (FC-43) Excellent 
Perfluorodecalin (FDC) Fair 
Perfl uromethyl decal in (FMD) Fair 
Perfl uorobutyl terahydrofu ran (FC-75) Fair 
Perfl uoroadamantane Fair 
Perfluorodimethyladamantane Excellent 
Perfl uorodecane Fair 
Perfluorodi-tert-butylether Good 
Freon E3 Excellent 
Freon E4 Excellent 
Freon E5 Excellent 
(Yokoyama et al. 1975; Clark et al. 1975; Clark 1974; Green Cross Technical 
Information 1975). 
(Geyer 1975) 
"' 
"' 
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is used for emulsifying PFCs, there should be no objection to its use for 
systemic infusion. Yolk phospholipids alone, are weak surfactants, and are not 
capable of emulsifying all kinds of PFCs. For example, when FDC is mechanically 
emulsified with this agent, it tends to agglomerate and form coarse particles 
within a few days. Yokoyama (1975) found that the FCD/yolk phospholipids 
emulsion becomes stable when a small amount of some fatty acid and glycerol is 
added. 
Some investigators have been unable to duplicate the life-saving effect 
reported by the pioneers, but it now seems likely that this is a result of 
variability of the preparations, particularly particle size distribution in the 
emulsions. 
Once Fluosol-DA 20% had been prepared as a blood substitute, clinical studies 
in seven traumatically decerebrate patients were carried out. These subjects 
were given infusions of the emulsion at dose level ranging from 200 to 1500 ml. 
No adverse effects were discovered in these patients. In 1979, twelve healthy 
Japanese volunteers received infusions of 20 to 500 ml without ill effects. To 
date over 200 infusions of Fluosol-DA 20% have been administered in Japan. In 
1980, clinical trials on the basis of emergency treatment began in the U.S.A. on 
Jehovah's Witness patients. The patient with the lowest hemoglobin level (1.6 
gm%) to receive the emulsion, and survive the surgical procedure, was reported by 
Tremper and Lapin in 1981. 
V-i-2 PATHOPHYSIOLOGY OF FLUOSOL-DA 20% 
The main ingredients of Fluosol-DA were chosen on the basis of relatively 
rapid elimination from tissues. A further consideration was the feasibility of 
preparing stable emulsions. The half-lives of FDC and FTPA, calculated from the 
expiratory excretion rate, are 7 and 65 days respectively. The calculated 
Table IX: Comparison of tissue retention of FOG and FTPA in rats following 
intravenous injection of emulsion is each substance 
Tissues 
Liver 
Spleen 
Kidney 
Lung 
Time after injection 
I week 
2 weeks 
4 weeks 
1 week 
2 weeks 
4 weeks 
1 week 
2 weeks 
4 weeks 
1 week 
2 weeks 
4 weeks 
tr: trace; less that 10mg/g wet tissue 
n.d. not detected; less than 1 mg/g wet tissue 
% of given dose 
FOG 
8.50 
0.50 
0.09 
4.00 
0.40 
0.20 
0.04 
n.d. 
n.d. 
tr. 
n. d. 
n. d. 
FTPA 
10.40 
4.60 
2.30 
6.90 
5.80 
1.20 
0.03 
tr 
n.d. 
0.01 
tr 
n. d. 
(Green Cross Manual) 
"' 
" 
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overall half-life of Fluosol-DA 20% is 8.9 days (Yokoyama et al. 1975). 
Researchers have been concerned with organ retention of fluorocarbons and 
Table IX shows the comparative data of retention of FDC and FTPA in the main 
organs of rats following intravenous injection of emulsions of each substance. 
Each of the PFC were emulsified to an identical particle size of about 0.1 micron 
diameter (Yokoyama et al 1974). In the case of FDC, yolk phospholipids were used 
as the 
of PFCs 
emulsifying agent and for FTPA, Pluronic F-68 was used. The concentration 
in 
dose of 4 
organs was determined 4 weeks after injection of the substances at a 
g/kg body weight. Quantitative determination of PFCs throughout this 
study was made by gas chromatographic means. 
As seen in Table IX, both PFCs were taken up in the liver and the spleen in 
the majority of animals and the maximum deposition in these organs occurred at 4 
days after injection. Significant differences were found in the elimination rate 
between the PFC emulsions. The concentration of FDC retained in the liver at 4 
weeks after injection was far less that 0.1% of the given dose, while that of 
FTPA was about 3%. 
PFCs are mainly excreted through the lungs and the elimination is 
exponential. The retained amounts of the substances in the body were calculated 
by summing the total amounts of expiratory compounds excreted. Excretion has 
also been found via the skin and the biliary tract, but the amounts excreted are 
very small in comparison to those leaving via the lungs. The size of the particles 
is apparently important in relation to the retention of PFCs, the larger 
particles being more rapidly removed from the blood stream than the smaller ones. 
In rabbits, the half life of a fine PFC emulsion with an average particle size of 
0.1 micron, is about 85 hours, while that of a coarse emulsion, with average 
particle diameter of 0.25 micron, is about 30 hours. The particle size 
significantly influenced the deposition rate of particles in the reticulo-
endothelial systan of the liver and spleen, and was also closely related to the 
toxicity of the emulsion. 
A major proble11 of PFC emulsions as artificial blood substitutes has been 
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that the compounds are retained in the tissues of animals for long periods of 
time, especially in the liver and spleen. In order to solve this problem, 100 or 
more mixtures of PFCs have been examined by many workers. Sixteen different PFC 
substances were examined by Naito et al. (1978). They found that compounds which 
have a high vapor pressure (exceeding 20 mm mercury) caused lung emphysema and 
are highly toxic. 
The excretion rate is roughly proportional to the vapor pressure of each 
substance. The half-life of Perfluorodecalin(FDC), the most rapidly excreted, is 
7 days and the amount retained in the body at 50 days after i nj ecti on was 1 ess 
than 1%, while the half-life of FC43 was about 900 days. FTPA half-life is 64.7 
days. 
FDC has been found to be the best of the available PFCs with respect to the 
rate of excretion, but it has been difficult to prepare a fine and stable 
emulsion of this substance. In order to improve the performance of the 
perf1uorodecalin emulsion, a comprehensive screening programme was enacted to 
find a suitable emulsion as an artificial red cell substitute, stable both in 
vivo and in vitro. After various trials, the combined use of FDC and FTPA was 
found to produce a fine and stable emulsion. FTPA was selected as one of the 
components of the blood substitute because of its low toxicity and relatively 
rapid elimination from the body. The half-life in rats is about 65 days. It is 
longer than that of FDC, but still shorter than that of the other perfluoro-
alkylamine compounds. A mixture of 7 parts decalin and 3 parts of propylamine 
was selected as the best formulation. 
The perfluorochemical emulsion, which was named Fluoso1-DA, is an emulsion 
consisting of 20% perfluorochemical, that is 7 parts of FDC and 3 parts of FTPA, 
Fluronic-F68 and yolk phospholipids as emulsifiers, and glycerol as a stabilizer. 
To furnish the preparation with physiological osmolarity and oncotic pressure, 
Krebs-Ringer's bicarbonate solution and hydroxyethyl starch (HES) were added. 
The volume of oxygen dissolved in Fluosol-DA changes linearly with P02 
according to Henry's law. The uptake and release of oxygen is completely 
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Fig 4 Electron-micrograph of 'Fluosol-DA 20% emulsion 
The dark beads in the center are polystyrene 1 atex 
particles of 0.1 micron in diameter as the marker. 
The particles surrounded by dark dots (phospholipids) 
are particles of perfluorochemical substance. 
Table X: Distribution of FDC and FTPA in tissues of dogs exchange-transfused with 
Fluosol-DA (Hct: 4-5). 
PFC concentration (mg/g wet tissue) 
Tissues 
1 month 2 months 6 months 
FDC FTPA FDC FTPA FDC 
Brain 0 0 0 0 0 
Heart 0 0 0 0 0 
Lung 0.11 0.63 tr tr 0 
Liver 18.97 29.43 tr 7.67 0 
Spleen 48.07 60.65 tr 5.38 0 
Kidneys 0.51 1.03 tr tr 0 
Adrenal s 4.30 5.62 tr tr 0 
Pancreas 6.88 8.81 tr tr 0 
Small Intestine 0.63 0.79 0 tr 0 
Large Intestine tr 0.70 0 0 0 
Stomach 0 0 0 0 0 
Testicle 0 0 0 0 0 
Muscle 0 0 0 0 0 
Femora 1 ~1arrow 4.05 4.92 tr 1.33 0 
Adipose Tissue 0.74 2.11 0 0 0 
Bile (mg/ml) 55.80 102.90 21.90 38.70 0 13.20 
FTPA 
0 
0 
0 
tr 
0.99 
0 
0 
0 
0 
0 
0 
0 
0 
tr 
0 
Yokoyama et al. 1977 
~ 
~ 
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reversible like hemoglobin and the rate is twice as fast as hemoglobin. 
Fluosol-DA can deliver an amount of oxygen equivalent to blood with a hematocrit 
of 30 to 40% when tissue P02 moves from 550 mm mercury to 50 mm mercury. 
However, Fluosol-DA in the circulation can only transport sufficient oxygen from 
the lung to peripheral tissues when the inspired p02 is high enough. 
The particle size distribution of the emulsion, which was determined by the 
centrifugal sedimentation method, is in a narrow range and 90% or more of the 
particles by weight were smaller than 0.2 micron in diameter. The particle size 
of the emulsion has also been confirmed by electron microscopy as shown in Figure 
4. The dark beads in the center of this picture are polystyrene plates, 0.1 
micron in diameter~ which were mixed in the emulsion as a control. The particles 
of Fluosol-DA are surrounded with a phospholipid layer which is 40 A thick. The 
size distribution of particles was found to be closely correlated with that 
obtained by the centrifugal sedimentation method. 
The retention of Fluosol-DA particles in the circulation is essential because 
the oxygen carrying capacity of Fluosol-DA is dependent on the concentration of 
PFC in the circulation. Rats and dogs had about 90% of their own blood replaced 
with Fluosol-DA and the elimination rate of PFC from the circulating blood was 
examined. In both species, the PFC was eliminated from the circulation according 
to the first order process, and the half-life of PFC in the circulation was 
calculated to be 14 hours in rats and 25 hours in dogs. In humans, it is not yet 
known. 
It has been well known that PFCs accumulate in some organs, especially in the 
liver and spleen, after leaving the circulation, and then are gradually excreted, 
unmetabolised, through the lungs. Table X shows the distribution and elimination 
of FDC and FTPA in dogs hemodiluted with Fluosol-DA until the hematocrit reached 
5%. The net dose given was about 15 grams per kilogram body weight and this is 
equivalent to around 5,000 ml of the emulsion per human adult. The concentration 
of both PFCs in the tissues of dogs was highest in the spleen and a level of 50 
to 60 milligrams per gram of tissue being was one month after administration. The 
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concentration in the liver was about half of that in the spleen. Smaller amounts 
of PFCs were also found in other organs after one month, but no PFC's were 
detected in the brain, heart, or testes. Two months after hemodilution, only 
trace amounts of FDC were found, while after six months FTPA was found at 
concentrations of about 1 milligram per gram of wet tissue. 
Rats were exchange transfused with Fluosol-DA under pure oxygen respiration 
until the hematocrit reached 1% and 4% corresponding to 98% and 92% replacement 
of their own blood, respectively. As a control, 3% hydroxyethyl starch (HES) 
solution was used. Bleeding from the carotid artery and replacement with an 
infusion of Fluosol-DA through the tail vein was repeated until the desired 
hematocrit was obtai ned. Fluosol-DA significantly prolonged the survival time of 
both groups of exchange transfused rats. Another study of distribution and 
elimination of FDC and FTPA, performed in dogs exchange transfused with 
Fluosol-DA until hematocrit 1 evel s fell bel ow 5%, showed that the concentrations 
of FDC and FTPA in tissues at 4 weeks after transfusion were highest in the 
spleen, showing at levels of 50 to 60 mg/g wet tissues. The concentrations of 
both PFCs in the liver were about a half of those in the spleen. Small amounts 
of both PFCs were also found in the lung, kidneys, adrenal, pancreas, intestine, 
bone marrow, adipose tissue and bile at 4 weeks, but no PFCs were detected in the 
brain, heart, or testes. FDC was eliminated faster from the tissues than was 
FTPA. At 2 months after hemodilution none, or only trace amounts of FDC were 
found, while about 1 mg/g wet tissues of FTPA was found in the spleen while 
traces were sti11 retained in the liver and bone marrow even after 6 months. Net 
doses of PFC given were equal to 15 g/kg. 
Similar results were also found in monkeys hemodiluted with Fluosol-DA until 
hematocrit reached 1%. At 2 and 4 months after hemodilution the monkeys were 
sacrificed and the concentration of PFCs in the tissues was determined. At 2 
months the concentration of both PFCs were found to be higher in the liver, 
spleen and bone marrow as compared to other tissues and no significant difference 
of the concentration in those tissues was observed between FDC and FTPA. 
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However, the concentrations of FDC so localized in these sites rapidly decreased 
and no FDC was detected in these organs at 4 months after hemodilution, while 
approximately 2 mg/g of FTPA was still found only in the liver and spleen. The 
net dose of PFC given was 25 g/kg. 
The rate of recovery of the blood components which are lost by the exchange 
transfusion with PFC emulsion is very important. It was shown that in rats with 
92% of their blood replaced with Fluosol-DA, plasma protein levels and white 
blood cell counts recovered completely within 3 days. The recovery of the 
hematocrit was somewhat delayed but it returned to the normal range within 2 
weeks. The respiratory function of the lung was well maintained during and after 
exchange-transfusions and no abnormalities in either kidney or liver function 
were found one week after the administration of F1uoso1. 
The amounts of oxygen that are carried by fluosol depends on the p02 of the 
solution. Unlike haemoglobin, which has the well known s-shaped dissociation 
curve, the uptake of oxygen of fluosol is directly proportional to p02. These 
relationships are illustrated in Fig 5. It can be seen that the amount of oxygen 
released in the tissues (at a p02 of 50 mm Hg) by a solution of fluosol saturated 
with oxygen at a partial pressure of approximately 500 mm Hg may in some cases be 
the same or even more than blood. 
The oxygen carrying capacity of Fluosol-DA was demonstrated in experiments 
using large animals such as rabbits, dogs, and monkeys. Occasionally, slight 
histological changes were observed in the pulmonary alveolar septa in the early 
period following transfusion but edema was rarely found in the lung. These 
changes were completely abolished within 6 days. The monkeys hemodiluted with 
Fluosol-DA remained in good health with no abnormal behaviour one year after the 
exchange (Gould 1982). 
0 rgan functions, which were temporarily damaged by the severe hemodi1 uti on, 
returned to normal levels within two weeks after hemodilution. At two days after 
infusion, significant changes were found by optical microscopy only in the liver 
and spleen. Kupffer cells in the liver were enlarged and proliferated, often 
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gathered together with fairly abundant, coarsely vacuolater or 'foamy' cytoplasm. 
Liver cells were not significantly affected but occasionally the cytoplasm were 
finely granulated or coarsely vacuolated. No necrotic changes occurred. In the 
spleen, reticular cells of the red pulp were swollen with coarsely vacuolated or 
'foamy' cytoplasm. Sometimes, the red pulp was filled with the 'foam' cells. 
The lymphoid follicles of the spleen were not significantly changed. These 
histological changes in the liver and spleen were maximal during the first 1 to 2 
weeks after transfusion and then gradually returned to normal. The cytoplasmic 
changes in both organs had virtually disappeared 4 months after infusion and no 
fibrosis was present. 
Electron-microscopic 
changes caused by 
examination revealed the 
infusion of Fluosol-DA 
details of 
in the 
the histological 
hematocytes and 
reticuloendothelial 
liver at 2 days 
reticuloendothelial 
cells 
after 
cells 
(Naito and Yokoyama, 1978). Electron-microscopy of the 
a single injection of Fluosol-DA demonstrated the 
filled with clusters of vacuoles. Hepatocytes showed 
some vesicles which contain small vacuoles surrounded by a membrane. However, 
these vacuoles were commonly isolated from organelles with electron dense 
membranes, so that substantial changes were not recognised in endoplasmic 
reticulum, mitochondria and the Golgi 's apparatus. The vacuoles found on 
electron-micrographs have been interpreted as being PFC particles because the 
amounts seem to be in proportion to the amount of PFC retained in the tissues. 
At 4 months after infusion, no PFC particles in the hepatocytes were observed; 
the vacuoles in some reticuloendothelial cells were still retained, but markedly 
decreased in number as compared with those at early stages after infusion. 
Histopathological studies in rats given 40 ml/kg body weight revealed mainly 
'foamy' changes in the liver and spleen at 2 weeks but disappeared at 4 months 
(Naito and Yokoyama, 1978). In monkeys, histopathological changes were noted 
after Fluosol-DA in a dose of 25 g of PFC/kg bodyweight (OhYanagi et al. 1977). 
The light and electron microscopic findings of the liver showed that PFC 
particles were intensively taken up by the Kupffer cells, but hardly at all by 
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the endothelium of the sinuses or hepatocytes. PFC particles diminished in their 
amount with the lapse of time after the infusion of PFC emulsions. No 
abnormalities of the organellae were observed in the hepatocytes. 
The glomeruli and proximal tubules of the renal cortex were histologically 
normal both at 2 and 4 months after infusion. On the other hand, some 
pathological findings, such as vacuolar or atrophic degeneration with inter-
stitial cell proliferation, were recognised in some parts of the distal tubules 
of the medulla. As the tubules are one of the most sensitive organs with respect 
to hypoxia, these findings would seem to indicate repair processes following mild 
localized tubular necrosis occurring during exchange transfusion. Evidence of 
edema was noted in the lungs which disappeared after 2 months. 
In all of the laboratory experimentations with rats, dogs, and monkeys, no 
evidence of carcinogenicity were noted (Naito and Yokoyama, 1978}. 
Our experience with humans revealed histopathological findings very similar 
to that of the findings in rats and monkeys. Liver sections in the early stages 
after infusion with Fl uosol-DA have revealed enlargement, vacuolization and 
increase in size of the Kupffer cells lining the sinusoids. The cytoplasmic 
vacuolization varies from coarse to fine. The hepatocytes were not significantly 
affected nor was evidence of necrosis observed. Splenic sections have demon-
strated early sinus histiocytosis with cytoplasmic vacuolization- a feature 
which has been observed in experimental animal models. 
Lung sections have revealed a variety of non-specific changes in the early 
stages such as pulmonary edema, vacuolated macrophages within alveolar spaces 
(heart failure cells} and in several instances, the presence of a hyaline mem-
brane lining the luminal surface of the alveolar walls. Renal tissue alterations 
have not been observed to any significant degree. 
We noted elevations of SGOT, SGPT, and alkaline phosphatase immediately after 
the infusion of Fluosol-DA 20%. The rise of the liver enzymes correlated with 
the amount of emulsion given. No changes were noted in the blood chemistry. 
Marked increase in the reticulocyte count were observed following the infusion. 
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Fluorocrit levels increased proportionately to the amount of PFC given. No 
evidence of carcinogenicity was observed in any of our patients 2 years after 
infusion. 
We have not used Fluosol-DA 20% on patients with: 
a. pulmonary i nsuffi ci ency (A.R.O.S.) 
b. liver dysfunctions 
c 0 renal i nsuffi ci ency 
d. allergic reaction 
e. positive Coombs test 
f. coagulation defect 
Our experience, and that of the Japanese investigators, has demonstrated the 
safety and feasibility of using PFC as a blood substitute. Although Fluosol-DA 
can never totally replace all of the functions that blood performs, it can be 
extremely useful in situations where blood is not available, or in patients who 
refuse blood transfusions on religious objections. 
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V-ii The Experimental Use of Fluorocarbons 
Fluorocarbon t~edi a ted Changes in Oxygen Supply in the I schemi cally Hypoxic 
Myocardium - Preliminary Report 
Introduction 
Cellular oxygen supply is dependent on: 
second, oxygen transport capacity of the 
first, pulmonary gas exchange; 
blood; third, capillary perfusion; 
fourth, oxygen diffusion through the capillary wall, the intercellular space and 
across the cell membrane. 
If adequate pulmonary gas exchange is maintained, and assuming no change in 
oxygen delivery to the tissue depends oxygen diffusion characteristics, 
furttlennore on oxygen transport capacity of capillary perfusate, tissue perfusion 
and distribution of the perfusate through the arteriolar-capillary network. 
The effects of occlusion of a supplying artery can be partially compensated 
for by collateral capillary perfusion resulting in a central totally ischemic 
area, surrounded by an area with partial collateral perfusion inside an area of 
active hyper-perfusion (i.e. Occlusion of a branc11 of the left coronary artery; 
Reeves et al. 1978). 
into the border areas of an infarcted region is not, Call ateral perfusion 
however, sufficient. The 
pressure 
capi 11 ary 
should be 
gradient 
pathway 
along 
to be 
main problem seems to be the decrease of the perfusion 
the capillary net because of increased length of the 
perfused. Hence, we postulated that blood viscosity 
considered to be a major factor determining flow ratio in cell aterally 
perfused areas. 
In the present preliminary 
electrodes directly implanted 
study this hypothesis was ex ami ned using micro-
i nto the myocardium and we tried to determi n'e to 
what extent increase of blood fluidity, produced by hemodilution, would increase 
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the collateral oxygenation of the ischemic area. 
In a second study, the influence of oxygen carrying low molecular 
fluorocarbon (Erdmann et al. 1982} added to the dilutate was studied to examine 
the reoxygenation of collateral perfusion of occluded areas. This was based on 
the hypothesis that the rather large oxygen carrying erythrocytes can probably 
not be transported along the elongated and narrow capillary system because of a 
too slow static pressure gradient. 
Materials and Methods 
Juvenile female Yorkshire pigs of 25 kg bodyweight were used in this 
preliminary investigation. 
Electrode Systems: 
The measurement of myocardial' p02 was accomplished with the use of four steel 
protected gold microelectrodes (Clark Electromedical Instruments} and a 
silver/silver chloride reference electrode. The gold microelectrodes, 200 
microns in diameter, were embedded in a thin flexible plastic plate.=_ 5 em x 2 
em, which was sewn onto the epicardium. The distance between the electrodes was 
1 em and they protruded 3 mm into the left ventricular wall to ensure contact 
with the myocardium. When the gold electrodes are negatively polarized, oxygen 
was reduced, causing a current to flow to replenish the electrons used up in the 
process. At a voltage of -800mV, this current is directly proportional to the 
oxygen concentration. To ensure partial pressure measurement, the electrode tips 
are covered with a plastic membrane, which also prevents protein poisoning and 
minimizes convection dependency. Because the currents are so small { 1-20 
namoamperes) measurements 
starting the experiment, 
solution, through which 
must be performed in an isola ted Faraday Cage. Before 
the electrodes were calibrated in a 37oC saline 
gases of known oxygen partial pressure were bubbled for 
equilibration. After the experiments the electrodes were again calibrated to 
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ensure reliability and to estimate any drift that had taken place. 
Anaesthesia and Monitoring 
Anaesthesia was induced with 
(30 mg/kg bodywei ght). 
an intraperitoneal injection of sodiurn 
After intubation with a cuffed endotracheal thiopentone 
tube the animals were ventilated with 0.5% fluothane in 100% oxygen using a 
r~i nivent ventilator adjusted to maintain the arterial pC02 at between 35 and 45 
mm Hg. Pancuronium bromide was used to maintain muscular relaxation and this was 
administered intravenously using a Braun Melsungen Perfuser adjusted to 
administer the drug at a rate of approximately 0.5 mg/kg per hour. 
Through an incision in the groin an arterial catheter was introduced into the 
femoral artery and advanced into the aorta. A venous catheter was introduced 
into the femoral vein and advanced into the inferior vena cava. A seven french 
gauge K~IA thennodilution catheter was introduced into the other femoral vein and 
advanced under pressure monitoring into the pulmonary artery. The arterial line 
was connected to a Gold Statham P23ID pressure transducer and the pulmonary 
artery line of the Swan Ganz and the central venous pressure line were connected 
to Gold Statham P23DC transducers. These together with a Millar microtip 
pressure transducer PC470, which was introduced into the left ventricle via the 
carotid artery in the neck, were fed into a 12 channel Grass 70 polygraph and 
recorded on paper using a Gras-s ink writing oscilligraph. 
Using the above instrumentation the following parameters were monitored: 
systemic and pulmonary artery pressure, central venous pressure, pulmonary 
capillary wedge pressure, left ventricular pressure, and left ventricular dp/dt. 
Cardiac output was detenni ned by thermodi 1 uti on using a KMA thennodi 1 uti on 
cardiac output computer model 3500. Arterial blood was withdrawn at regular 
intervals for blood gas analysis using a Radiometer ABU acid base laboratory. 
Haemoglobin was estimated using a Radiometer OS~12 hemoxymeter. The thorax of the 
animal was opened using a sternal splitting technique and the pericardium was 
reflected. The pig was moved into a Siemens electrically isolated Faraday Cage 
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to minimize noise interference and all lines were led outside via the grill 
1Windows' to transducers and recording apparatus. The pig lay on a warming 
mattress through which warm water was pumped by a GR! aquamatic K heater 
circulator module. The p02 microelectrodes protruding through the plastic plate, 
as described above, were sutured onto the epicardium after the electrodes had 
been placed in position in the expected area of distribution of the chosen branch 
of the 1 eft anterior descending coronary artery (LAD}. This was a branch that 
was constantly 
em above the 
observed issuing laterally and to the left from the LAD about 2-3 
apex of the heart. The electrical output from the electrodes was 
amplified by DC amplifiers inside the Faraday Cage and the resulting signals were 
fed into Rikadenki electronic recorder model KA60. The experimental arrangement 
is demonstrated diagramatically in Fig. 6. 
After allowing time for stabilization of the preparation of ligature was 
placed around the chosen branch of the LAD and the vessel was occluded. In one 
animal no treatment was administered, and after four hours it was sacrificed by 
ventilating with 100% nitrous oxide - this usually results in total cessation of 
circulation within five to ten minutes. The heart was removed and examined 
macroscopically and microscopically for signs of infarct. 
In the second animal bleeding was begun after one hour of vascular occlusion. 
20 ml of blood per kilogram bodyweight was removed and then immediately replaced 
with the same volume of a fluorocarbon solution (fluosol - DA 20%} the animal was 
again sacrificed four hours post-clamping and the heart ex ami ned by the 
pathologist. 
In the third animal, dextran 40 (40,000 molecular weight) was used in place 
of the fluorocarbon solution; again pathological examination of the heart was 
carried out after the animal had been subjected to an acute hypoxic death. A 
schematic plan of the experimental protocol is shown in fig. 7. The fluorocarbon 
and dextran treatments were completed between one and two hours postclamping; the 
two hours post-clamping values as presented in the results section thus represent 
values obtained just after the infusion of dextran or fluorocarbons. 
Left IntraventricuLaL+---,£~~41 
Pressure Line 
~L----{-----------Arterial Line 
~~----------Swan Ganz 
catheter 
Fig 6 Schematic diagram of the experimental arrangement- 4 microelectrodes, 200 
microns in diameter were inserted in the di stri buti on area of a tenni nal branch 
of the LAD. 
0 hr 
Dextran 
Bleeding or 
F!uoso! 
1 hr 2 hr 3 hr 
Anesthesia and Monitoring 
LAD Branch occluded 
Fig 7 Sequence of experimental procedures 
4 hr 
Histological 
examination of 
the heart 
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Pathological Examination: 
After macroscopic inspection, three slices were cut from each heart, about 
0,5 em thick. Slice 1 was taken from just distal to the point of occlusion of 
the artery the anterior left ventricular wall in this specimen represents the 
direct area of supply of the occluded artery. Slice 2 was about 1 em above Slice 
1, (in the direction of the atrio-ventricular valves} and Slice 3 was 
approximately 2 em above Slice 2. The anterior ventricular wall in Slices 2 and 
3 lies under the area covered by the electrode bearing plastic plate. 
Tissues blocks were taken from any macroscopically abnormal area observed, or 
if no abnormality was 
left ventricular wall. 
These blocks were fixed 
present an 'at random' block was taken from the anterior 
Per heart, two to three tissue blocks were obtained. 
for 24 hours in 10% formalin and then embedded in 
paraffin wax. Five micron thick sections were taken and stained with the 
hemotoxolin-azophloxin technique. 
Results 
Myocardial Oxygenation Changes: 
It was impossible to know exactly where the most hypoxic area was likely to 
be situated following occlusion of the chosen branch of the left anterior 
descending coronary artery. Therefore, four electrodes, as described above. were 
placed throughout the area were ischemia was to be expected. After occlusion, 
pO~ dropped in those areas where perfusion was decreased while in the unaffected 
areas it remained at the original level. In the following description we have 
concentrated on describing the changes in the area ¥-'hich was most ischemically 
hypoxic. All p02 tracings were therefore studied and the most hypoxic area was 
chosen as being in the region of the electrode demonstrating the greatest 
percentage fall in p02 one hour after ligation of the artery when comparing the 
values to the preligation values. The readings from that electrode are 
presented. 
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Fig 8 Changes of myocardial p02 in the experimental groups. Baseline measurements 
were taken of the microelectrode showing the greatest percentage fall from the 
preocclusion value~ 
No treatment Cardiac Output c 
" Systemic Vascular Resistance-0 
" " Haemoglobin Concentration --1:. 
Percentage change Dextran Cardiac Output II Systemic Vascular Resistance-• 
+100 Haemoglobin Concentration--"' Fluosol Cardiac Output II 
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Fig 9 Hours after occlusion of Terminal Branch of LAD 
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Figure 8 is a graphical representation of the percentage changes in p02 
taking place in the most hypoxic areas in three pigs, whereby the changes are 
expressed as percentage change from the values one hour after vascular occlusion; 
i.e. the post-occlusion hypoxic value is taken as the baseline for further 
changes. 
As can be readily seen in the pig that received no treatment following 
occlusion, there was a steady drift downwards of the myocardial p02 from the one 
hour post-occlusion value. Four hours after ligation the value was 21.4% lower 
than one hour after ligation. 
In the case of the pig treated by bleeding 20 cc of blood per kilogram body 
weight and replacement by the same volume of dextran 40, a dramatic 91.7% fall of 
p02 was observed at two hours post-ligation i.e. immediately following infusion 
of dextran. At four hours this was still decreased 86.1% from the baseline. 
In the pig treated by bleeding followed by reinfusion of the same volume of 
fluorocarbon solution, a marked rise was observed in the myocardial p02 in the 
hypoxic area. This amounted to 77.8% at two hours after ligation. After a 
further two hours there had been a further rise to produce a value of 100% 
increase above the direct past-el ampi ng value. 
Cardiovascular Changes: 
Percentage changes in cardiac output, systemic vascular resistance, and 
haemolgobin concentration are represented graphically in figure 9. 
Both fluorocarbon and dextran treated pigs showed rises in cardiac output and 
falls in vascular resistance after their respective treatments. Changes seen in 
the dextran pig were more pronounced than those in the fluorocarbon pig - cardiac 
output in the dextran pig rose by 57.1% and 61.1% at the two and four hour 
past-el ampi ng respectively while its systemic vascular resistance decreased by 
32.6% and 38% over the same period of time. In the case of the fluorocarbon 
treated pig, cardiac output rises of 36.8% and 34.6% were measured with 
corresponding 21.2% and 24.6% decreases in systemic vascular resistance. 
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A greater percentage fall in haemoglobin concentration was observed in the 
dextran pig as compared to the fluorocarbon treated one - decreases of 45.1% and 
36.3% in the former as against 20.8% and 32.1% in the latter. 
No significant changes of blood pressure (i.e. perfusion pressure) were 
observed in any of the animals. 
Pathological Changes: 
Macroscopically it was ascertained that the chosen branch of the LAD was 
completely occluded. Four small holes were present over the left and right 
ventricular wall on each heart representing the sites of insertion of electrodes; 
in addition holes made during suturing of the plastic electrode plate were 
visible. 
Inspection of the tissue specimens revealed heamorhagic mottling in the 
anterior left anterior wall in Slice 1 from all hearts. In the no treatment 
heart, no discolouration was seen in Slices 2 a'nd 3 whereas, in the dextran 
heart, slight haemorrhagic discolouration was observed in the left anterior 
ventricular wall in both Slices 2 and 3. The fluorocarbon treated heart showed 
slight haemorrhagic mottling of the anterior left ventricular wall in Slice 2 but 
not in Slice 3. 
Microscopically, all hearts showed marked epicardial infiltration with 
polymorphonuclear leucocytes. The site of insertion of the electrodes was 
clearly indicated by a 'hole' in the myocardium, surrounded by eosinophilically 
charged myocardial fibres. Eosinophilia of the myocardium was taken, not so much 
as a sign of ischemia, but more as an indication of mechanical damage. 
•waviness• of the myocardial fibres was used as a •marker• of ischemic change 
(Bouchardy and Manj o, 1974). Areas of extensive coherent 'waviness' were 
demonstrated in the immediate area of supply of the occluded artery (Slice 1) in 
all hearts. Similar areas of 'waviness' were observed in the anterior left 
ventricular wall in Slices 1 and 2 in both the no treatment and dextran treated 
hearts. In contrast, in the fluosol treated heart only localised 'waviness' of a 
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few myocardial fibres was observed. 
Discussion 
The hypothesis was 
the flow resistance 
studied that decrease in viscosity and hence a decrease in 
along ateriolar-capillary collateral circulation should 
increase collateral perfusion of the ischemic areas and therefore increase oxygen 
supply. 
Although dextran decreased flow resistance decisively (as evidenced by 
decreased systemic vascular resistance) with a corresponding increase of cardiac 
output and decrease of haemoglobin concentration, oxygenation of the ischemic 
areas deteriorated more than in the untreated animal. 
This 1 eads to the conclusion that, under conditions of ischemic hypoxia, 
viscosity per se is not the determining factor in tissue oxygenation - even in 
the presence of increased cardiac output and assumed increased tissue perfusion. 
To study whether this was a question of increased perfusion outside the 
ischemic areas or of inability of oxygen carrying erythrocytes to penetrate the 
ischemic capi 11 ary bed (although erythrocyte-free p 1 asma perfusion was 
increased), a molecular small volume oxygen carrying substance in the form of the 
plasma expander fluosol-DA 20% was used for blood replacement. In spite of the 
fact that this ready-for-use blood substitute did not produce as much apparent 
changes in viscosity as dextran (less decrease of the systemic peripheral 
resistance and haemoglobin concentrations) and therefore less increase of cardiac 
output, (and hence less tissue perfusion), tissue p02 was decisively improved in 
the ischemic area. 
Thus the inability of red cells to be forced through an elongated collateral 
perfusion pathway to supply an area ischemically cut off from the direct blood 
supply, would appear to be a major contributing factor in determining the 
ultimate infarct size. 
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The pathological findings would indicate that fresh myocardial infarction was 
present in all hearts, however, in the fluorocarbon treated heart the infarcted 
area was localised and limited in extent to the immediate area of supply of the 
occluded artery while in the no treatment and dextran treated hearts the 
infarction extended far beyond this expected area of immediate supply. This would 
indicate that though fluorocarbon treatment cannot prevent myocardial infarction 
it can significantly reduce its extent. 
The present experiments suggest that low volume oxygen carrying molecules can 
indeed penetrate collaterally perfused capillary beds to replenish oxygen supply. 
This may well indicate a promising approach to future clinical treatment of 
fresh infarction. 
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V-iii The Clinical Use of Perfluorocarbons 
The Preoperative Treatment of Severely Anemic Patients with a Perfluorochemical 
Oxygen Transport Medium Fluosol-DA 20% 
This study has been published in the New England Journal of Medicine. 
ABBREVIATIONS 
Cardiac Index - CI 
Left Ventricular Stroke Work Index- LVSWI 
Oxygen Delivery - 02 Del 
Total body oxygen consumption - V02 
H eiTlatocri t - Hct 
Fluorocrit - Fct 
Partial pressure of oxygen (arterial)- Pa02 
Oxygen content (arterial) - Cao2 
Hemoglobin 02 saturation (arterial) - Sa02 
Arteriovenous oxygen content difference - avD02 
Hemoglobin - Hb 
Perfluorocarbons - PFC 
Partial pressure of oxygen (mixed venous) - Pvo2 
Oxygen content (mixed venous) - Cvo2 
Hemoglobin 02 saturation (mixed venous) - Sv02 
Positive End Expiratory Pressure - P£EP 
Transcutaneous partial pressure of 02 - Ptc02 
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Introduction 
In 1965, Leland Clark dramatically demonstrated the oxygen carrying capablity 
of perfluorochemicals (PFCs) with the survival of mice completely immersed in the 
1 i qui d. Si nee then, work has progressed to the production of stable inert 
emulsions that act as red blood cell substitutes during complete exchange 
transfusions in animals. After studies with decerebrate human subject.s in 1979, 
adult volunteers were given the PFC emulsion, Fluosol-DA 20% in Japan (Green 
Cross Corporation, Osaka, Japan). Last year we reported the first 
comprehensively monitored administration of Fluosol in the preoperative treatment 
of severe anemia. This uncontrolled, non-blind study of the effects of 
Fluosol-DA 20% commenced in November 1979, in patients who required emergency 
medical/surgical treatment, who refused blood or blood products, and for whom no 
other acceptable medical treatment existed. The following study reports the 
results of the comprehensive monitoring of seven anemic surgical patients and 
represents the first clinical trial of PFC red cell substitute in the United 
States. 
The objectives of this study were as follows; first, to evaluate the clinical 
safety of Fluosol administration - this was with respect to fluid overload and 
possible adverse reactions; second, to comprehensively monitor hemodynamic and 
oxygen transport variables before and after Fluosol administration - this was to 
determine if Fluosol transported the expected volume of oxygen, based on its 
known oxygen solubility, and to document the possible physiologic responses to 
the increase in oxygen content after Fluosol administration; third, to determine 
the reliability of calculated oxygen content determinations versus directly 
measured oxygen content values obtained in the clinical setting. Since the 
direct measurement of oxygen content is not available at most hospitals, whereas 
Pa02 is standard, we hoped to determine if an estimate of the Ca02 value based on 
Pa02, Sa02, hemoglobin and fluorocrit could accurately represent the measured 
Ca02 value. 
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Table XI 
-·-----
AG>. 5<> BOOY WEIGHT 
,, 
)I M 
'" 40 F 45 
]) F 78 
28 M 80 
59 F 91 
51 M 102 
5t 28 M 64 
"An.,.,theSla was mainta1ned "'1th enOurane, oxygen, and pancuronoum 
•The study was lcrmmated after a clinical rcac1ion to a I<« do>e of fluosol 
Patients' Clinical Data. 
[l,_GNO!liS HE.\l0GI.U81,_ SuRGEaY • 
gjdl 
Ulcerative colius 1.9 Colectomy and ileostomy 
Dysfunctional uterine 3.5 Total abdominal 
bleeding hysterectomy 
U1erine fibroid 4.5 Total abdominal 
bleeding hysterectomy 
Upper-gastrointestinal-tract 6.6 Suture ligation of 
bleeding gastric ulcers 
U pper-gastrointestinaHract 7.2 Suli.lfC ligation of 
bleeding gastric ulcers 
U pper-g·astrointe:mnal-tract 7.5 Suture ligation and repair 
bleeding of hiatal hernia 
U pper-gastroi ntesti n al-tract 3.9 None 
bleeding 
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Materials and Methods 
Clinical Subjects: 
The patient admisssion criteria was as follows: First, the patients had to 
be anemic, hemoglobin less than 8 gram%, and in need of surgical treatment if 
actively bleeding. Second, the patients were without a history of hepatic, renal 
or pulmonary disease. This was not only because of possible toxic effects, but 
also to insure that patients would be able to restore their own hemoglobin if 
Fluosol were able to help them survive the immediate surgical trauma. Also, if a 
patient were unable to achieve a high Pa02 value (300 torr), the oxygen carried 
by Fluosol would be minimal and not warrant the use of Fluosol. Third, the 
patients refused blood or blood products. 
Seven patients were admitted to the study. Their clinical data and mean 
hemoglobin values are presented in Table XI. The patients ages ranged from 28 to 
59 years, with a mean of 35 years, while their mean hemoglobin values ranged from 
1.9 to 7.5 gram %, with a group mean of 5.1 gram%. All the patients were 
actively bleeding when they entered the study and had failed with conservative 
therapy. Two of the seven patients had symptomatic reactions to a test done with 
Fluosol and were discontinued from the study. All five patients receiving Fluosol 
tolerated surgery well, although the most severely anemic patient (mean Hb = 1.9 
gram %) died on the fifth postoperative from multiple complications unrelated to 
Fluosol. 
Preparation and physiologic measurements: 
Swan Ganz and arterial catheters were placed in each patient. Each data set 
included systemic arterial, pulmonary artery, wedge (WP) and central venous 
pressures (CVP}, heart rate, central blood temperature, cardiac output, Fi02, 
arterial and mixed venous blood gases and blood oxygen contents, hematocrit, 
fluorocrit (% of perfluorochemical in a blood sample analogous to the 
hematocrit}, and transcutaneous OXYgen (Novametrix Medical Systems, Wallingford, 
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Ct.). Cardiac output was determined by the thermodilution technique and taken in 
duplicate. Blood gas samples were taken anaerobically and analyzed for gas 
tensions and pH with either a Radiometer BMS-3, l~ark-2, or IL282 blood gas 
analyzer, and for oxygen content with a LEX-02-CON-TL (Lexington Instruments, 
Waltham, 1·1ass.). The fl uorocrits were determined by centrifugation of blood 
samples in capillary tubes for 12 minutes at 10,000 rpm instead of at the 
required speed of 12,000 rpm for 10 minutes. The accuracy of this method was 
checked against direct gas chromatographic blood analysis. 
Derived variables were calculated by standard formulas. A total of 89 data 
sets were taken for the five patients completing the study, (18 ~ 3 data sets per 
patient). Approximately 2.5 ml of blood were required for each data set. After 
placement of Swan-Ganz and arterial catheters, three sets of baseline data were 
taken with the patient breathing room air. (This was not done with the most 
anemic patient, Hb = 1.9 gram %). This was followed by three sets of data 
collected with the patient breathing maximal oxygen by mask. 
The patient was then given a 0.5 ml test dose of Fluosol, intravenously. If 
no adverse reactions were noted, the F1uoso1 infusion was started at 1 ml per 
minute and gradually increased to a maximum rate of 10 ml per minute. WP was 
monitored during Fluosol administration and furosemide was given to WP 18 em 
water. The total dose of Fluosol given was 20 ml per kilogram of body weight. 
Data sets were again call ected with the patient breathing room air and maximal 
inspired oxygen by mask. The patients were then taken to surgery where data sets 
were 
into 
call ected 
the study, 
approximately every 15 minutes. The last three patients entered 
had complete blood counts taken just before the test dose of 
Fluosol, and 5 and 10 minutes after the test dose (discussed below). 
Results 
Preoperative Control Values: 
The hemodynamic and oxygen transport data for the five patients are presented 
TABLE XII Hemodynamic and Oxygen Transport Values (n=5) 
Pre Fluosol After Fluosol 
Variables, Units Normal Values Low Fi02 High Fi02 Low Fi02 High Fi02 
HR beats/min 68-76 106 + 16 102 + 13 114 + 13 10 + 15 
MAP mm/Hg 85-95 86 + 10 87 + 7 89 + 15 91 + 20 
WP mm/Hg 3-13 5.4 + 1.0 5.1 + 1.0 14 + 2 14 + 2 
CI L/mi n/m2 2.8-3.4 5.3 + 1.6 5.1 + 1.4 5.3 + 2.0 4.6 + 1.0* 
-
L YSW gm/m2 50-62 56 + 8 55 + 12 55 + 14 53 + 5 
02 Del ml/min/m2 550-650 354 + 34 341 + 104 364 + 54 375 + 132 
-
V02 ml/min/m2 115-215 99 + 23 92 + 20 92 + 9 112 + 18* 
Hct% 36-48 14.1 + 6.0 14.1 + 6.0 14.! + 6.0 14.1 + 6.0 
Fct% 0 0 0 5.3 + 0.5 5.3 + 0.5 
Fi02 21-100 21 80 35 + 18 100 
P a02 torr 92-98 82 + 13 299 + 49 103 + 30 363 + 91 
Ca02 ml /dl 17-20 7.2 + 2.0 7.3 + 3.2 7.2 + 2.2 8.1 + 2.8** 
Pv02 torr 34-42 37 + 2 44 + 5 42 + 3 70 + 27* 
Cv02 ml /dl 12-15 5.2 + 1.7 5.3 + 2.0 5.3 + 2.0 5.7 + 3.5* 
v Sat % 72-78 69 + 5 78 + 3 75 + 2 90 + 6* 
-
P tc02 torr 65-85 56 + 14 299 + 96 92 + 42 410 + 113 
* p<O .05 Transcutaneous/arterial 02 correlation 
** p<0.005 Correlation coefficient, r = 0.96 
Slope, s = 1.15 
intercept, i = 28 
number of data sets, n = 89 
"' ~
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in Table XII for the four parts of the study: control data before Fluosol at low 
and high Fi02, and after Fluosol infusion at low and high Fi02. These five 
patients were in a hyperdynamic state to compensate for their anemia as seen by 
the high values of heart rate and cardiac index. They were able to achieve nearly 
60% of the normal rate of oxygen delivery which brought them to within 86% of the 
normal range of total body oxygen consumption (V02). Except for the most 
severely anemic patient (Hb- 1.9 gm %), who has always treated with supplemental 
oxygen, the four other patients tal era ted breathing room air in spite of mean Hct 
and Ca02 values nearly 1/3 of normal (Hct 14.1:!:: 6.0%, Ca02 7.2 + 2.0 ml/dl). 
When the patients were treated with high FI02 using a tight fitting, 
nonrebreathi ng mask, there were no statistically s i gni fi cant changes in 
hemodynamic parameters. The Pa02 increased from 82 torr to 299 torr. 
Conseqently, the Ca02, Pv02, Cv02, and Sv02 all increased. The Ptc02 responded 
quickly and linearly to all the changes in Fi02. The 95% response time was 
approximately 2 minutes. A linear regression between Pa02 and Ptc02 values 
produced a correlation coefficient of 0.96. 
Effects of Fluosol Infusion: 
Prior to the infusion of Fluosol, a 0.5 ml test dose was given intravenously 
to each patient. Two of the seven patients had symptomatic reactions following 
the test dose and are presented in detail in the appendix 'Clinical 
Reactions'. The other five patients completely tolerated both the Fluosol test 
dose and the infusion, demonstrating only gradual increases in the WP. Two 
patients were treated with furosemide when the WP reached 18 em H20. As stated 
previously, complete blood counts were obtained immediately before and after the 
Fluosol test dose in three patients. All three patients had an immediate and 
transient fall in white blood count (WBC). The values decreased to 35% of 
baseline at 5 minutes after the test dose and returned to baseline WBC at 10 
minutes. This hematologic response will also be described in more detail in the 
appendix. 
TABLE XIII 
Patient No. Sex Fluosol 
S .E. /9 M 1,500 
0 .G. 17 F 1,000 
B.W./13 F 1,500 
K.W./12 M 1,500 
H.R./8 F 2,000 
#Blood Volume Index: 
M 2.74 F 2.37 (L/M2 body surface area) 
+ FCT = Fluosol Volume 
DTood volume + fluosol volume 
* Determined by gas chromatography 
Fluorocrit Determination 
Blood Volume# Measurement FCT 
4.0 3.2 
3.4 2.7 
4.2 2.4 
4.0 2.8 
4.9 3.0 
2.8 + 0.3 
X 0.2 
Calculated FCT+ 
5.5 
4.5 
5.3 
5.4 
5.8 
-
5.3 + 0.5 
GC* 
5.39 
co 
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OXYGEN CONTENT INCREASE 
DUE TO THE PERFLUOROCHEMICAL 
Low 
PaOz 
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Fig 10 The time course of Ca02-Cao2c (upper graph), Pa02 and Fct 
(lower graph) are presented above. The difference between 
Ca02 and ca02c represents the additional oxygen carried solely 
by the presence of the PFC. Note, this difference becomes 
significant only when Fluosol is present with high Pa02 
values. 
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After the 20 ml/kg nuoso1 infusion 1 the patients breathing low Fi02 (35 + 
18%) demonstrated no si gni fi cant hemodynamic or oxygen transport changes other 
than an increase in \0P (5.4 ~ LO to 13 ~ 4 em H20) and fluorocrit (0 to 5.3 + 
0.5%), None of the m:~1e( ct1anges in monitor·ed values could be attributed to the 
addition of Fluosol (Table XII). 
Fluorocrit values peaked approximately one hour after the completion of the 
infusion~ decreased to ha_lf the maximal value at 24 hours~ and were undetectable 
at 48 hours, The measured Fct values vJer~e half the expected values, 2.8 ~ 0.3% 
versus 5.3 + 0.5% (Table XIII), based upon the previous clinical experience, 
published literature and a calculation derived from the administered volume 
(calculated fluorocrit FctcL This v.Jas presumably due to the inability of the 
hospital centrifuge to attcrin the ~~equir'ed speed of 12~000 rpm. In a patient 
h1here the F ct was deterrni ned from mu"J tip 1 e samp 1 es by gas chromatography (F ctGC) 
the FctGC values agreed vlitfl the Fete values} F~t 2.8%, Fete = 5.39% (Table 
XIII). 
\~hen the patients VJete ventilated with 100% oxygen there Nere several 
s tati sti cal sigr.ihcant llemod_ynamic and oxygen transport changes. The V02 
increased from 92 to 112m! min-1m-2~ while the Ca02 increased from L2 + 2.2 to 
8,1 + 2,8 m1/dl at a Pa02 of 363 + 91 torr (Table XII), This increase in Cao2 
was sigificant.ly (p<0.005) greate1~ than the calculated CaOZ value assuming no 
Fiuosol (Ca02c) (Table XIV). rigure 10 presents the changes in CaOZ during the 
course of tile study" The d·ifference betvJeen Ca02 and Ca02c is the oxygen carried 
solely by the PFC. Ti:e differ·ence between these two oxygen contents becomes 
significant on·ly after Fluoso1 at high Pa02 values. This increase in oxygen 
content~ due so1 to tile PFC~ was approximately 0.7 ml/di at Pa02 363 + torr 
and a Fete of 5o3 + 0.5~b. During this time the Sv02 reached 90 + 6%. 
Tab'le XV presents the percentage of V02, 02 Del and Ca02 carried by the PFC 
a~.- its peak effectiveness (at maximal Fct and Pa02). Tf1e PFC supported 24 + 7% 
of tf1e V02 and 7 + 3% of tl·1e 02 Del and Cao2. In the most severely anemic patient 
the PFC was responsibl-e fm~ 26% of the VOZ and 12% of the 02 Del and Ca02. 
Table XIV Oxygen Content Comparison 
1 2 3 
Ca02 Ca02 Ca02F Pa02 n 
Without Fluosol 7.2 + 2.8 7.2 + 3.0 - 208 + 118 32 
With Fluosol 
at 1 ow Pa02 6.8 + 3.2 7.2 + 2.2 7.0 + 3.3 10.3 + 30 10 
With Fluosol 
at high pa02 7.5 + 2.7* 8.1 + 2.8 363 + 2.7 363 + 91 47 
1. Calculated by standard formulae, P102, Hb and 02 saturation assuming no Fluosol. 
2. Measured with Lexington Institute, LEX-02-Con-TL. 
3. Calculated with Fluosol, Ca02 = Ca02c + FCT x Pa02 x 3.315 x 104 
*With Fluosol at high Pa02, Ca02 is statistically significant (P<0.005) different 
from Ca02 and Ca02F (by student t test, the difference between the means: Paired 
data with unknown population variances). 
~ 
0 
0 
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Table XV Oxygen Transport by the Periluorochemical at High Partial Pressure of Arterial Oxygen (Pa02)-
hTii'T Nu Ht"O(.UJDIS * I'Ll'ORO('RIT PaO, 
0\Y(..>'-·( ONS~MPTIO,; 
~/dl % !orr 
1.9 3.0 356 26 12 
3.5 2.7 386 26 
4.5 3.0 329 25 
66 2.8 456 31 
12 3.0 294 II 
Mean ±S.D. 24±7 7±3 
*To <onven hemoglobm value< to mllhm:Sio> per liter, mull!ply b) 0.6206 
tThe«: percentages represent the c•lculated contnbuuon that the oxygen transported <oldy by the pernuorochcm-
'cal made to these ox~gen-tran.pon values. I( the oxygen transported by the plasma phase is added. the mean value< 
inc·rcase lO approxomately 51 per cent of the oxygen consumptoon and 17 per cent of both the oxygen dehvery •nd the 
my~en content 
CH,'<GE "' 
C•RD'-C 1>-0U 
•HH I·LLOSOL 
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There were no significant changes in arterial carbon dioxide partial pressure 
(PaC02) or pH. Throughout the entire study period each patient's oxygenation 
status was continuously and noninvasively monitored with the Ptc02 sensor. 
In Table XIV, Ca02 is detennined in three ways and compared during three 
phases of the study. Ca02c is the content calculated by standard fonnul as 
assuming no Fluosol is present, Ca02 is the content directly measured by the 
LEX-02-CON-TL and Ca02F is the calculated content, taking into account the oxygen 
carried by the PFC. Before Fluosol, Ca02c and Cao2 are not significantly 
different. At low Pa02, after Fl uosol, all three oxygen content detenni nations 
are not significantly different. However, at high Pa02, after Fluosol, Ca02 and 
Ca02F are still not significantly different, but both are significantly (p<0.005) 
higher than Ca02c. 
Discussion 
Fluosol is known to transport oxygen and has supported life in experimental 
animals which have undergone exchange transfusion to Hct of 1%. We recently 
reported a case study describing extensive hemodynamic monitoring during Fluosol 
administration in a severely anemic surgical patient~ This paper presents 
statistically significant evidence of the amount of oxygen transported by the PFC 
alone when Fluosol-DA 20% is used in the clinical setting. 
Because PFCs carry oxygen by direct solubility, as does the plasma, at high 
Pa02 values the tissues will extract 75 to 80% of this dissolved oxygen before 
any significant oxygen is released from the hemoglobin. This is evidenced by the 
high Sv02 noted in these patients after Fluosol administration, Sv02 = 90 ~ 6% at 
Pa02 363 + 91 torr. In two patients the Sv02 reached 97%. It also must be 
considered that these results were achieved with a fluorocrit of only 5%. In 
addition to the statistically significant increase in Ca02 and Sv02, the only 
other variable with a significant increase was the V02. 
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There are two reasons why the oxygen transported by the PFC ernul si on might 
be more readily utilized by the tissues than the oxygen bound to hemoglobin. 
First, since the oxygen extracted from the blood is at a higher P02, there is a 
greater P02 gradient for diffusion into the tissue. Second, the PFC emulsion 
particle size is approximately 0.1 micron. This small size {1/70 the size of the 
RBC) would allow for flow through small capillaries at faster rates. Both of 
these phenomena would have contributed to the increased V02 found in this study. 
Glogar et al. {1981) demonstrated a substantial decrease in myocardial infarction 
size in experimental animals pretreated with PFC emulsions at high Fi02 values. 
The patients in this clinical trial were all hyperdynamic, mean C.!. = 5.3 + 
1.6 L/min/m2, to compensate for the decreased Ca02 due to the anemia. The mean 
C.!. decreased after Fluosol treatment to 4.6 + 1 L/min/m2, but the decrease was 
most dramatic in the more severely anemic patients, i.e. HB 6 gm%. These changes 
were somewhat confounded by the changes in plasma volume with Fluosol treatment, 
WP 5.4 em H20 before and 14 em H20 after Fluosol. If the patients had their 
control data taken at comparable WPs the decrease in C.!. might have been more 
dramatic. This was not clinically feasible. 
Note that, as expected, the only significant rise in Ca02 comes after 
administration of Fluosol at high Pa02 values. This is about 0.7 volume% or ml 
per deciliter at 400 torr at a fluorocrit of 5%. Although this increase may 
appear small, when taken in the context of severe anemia, and considering the 
consumable oxygen, which must be at a high enough P02 to diffuse into the 
tissues, this small val % of oxygen can be very significant. Since normal 
arterial blood oxygen content {Ca02) is 17 to 20 val%, an increase of 0.7 val % 
would not seem to be very significant. But in cases of severe anemia this 0.7 
val % may mean the difference between survival and non-survival. At normal blood 
flow rates {cardiac index, C.!.) the body consumes about 4 to 5 val% 
{arteriovenous difference {avD02)) of the 17 to 20 val %oxygen during each 
circulation through the peripheral vascular bed. Therefore, even in a nonnal 
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patient, this 0.7 vol % of oxygen comprises approximately 17% of the consumed 
oxygen. In severely anemic patients, like those in this study, whose avDo2s were 
approximately 2-3 val %, this same 0.7 val % carried by Fluosol (PFC) accounts 
for 20-40% of the consumed oxygen. 
The Ptc02 monitor was extremely valuable in treating these anemic patients. 
It allowed us to minimize blood gas sampling and to take the samples at the 
appropriate times; i.e. when the trend in Ptc02 values alerted us to changes in 
Pa02. When the most anemic (Hb 1.9%) patient was first evaluated he was in acute 
respiratory failure and needed preload adjustment and multiple PEEP studies 
before his Pa02 was sufficiently high enough to potentially benefit from Fluosol 
therapy. During this time we were able to titrate PEEP values without blood 
sampling by following Ptc02 and C.!. 
Clinical Safety: 
In five patients there were no symptoms associated with Fluosol therapy. One 
patient had very vague, subjective symptoms which lasted less than one minute. 
One other patient had a significant clinical reaction to a test dose, which 
resolved itself without treatment within 3 minutes. The underlying mechanism is 
unclear but probably involves the activation of a self-limiting complement 
cascade. The alternative pathway of the complement system has been implicated as 
initiating the reaction. The acute fall in WBC, noted in all patients 
subsequently evaluated from hematologic changes, might be involved in the same 
mechanism. It is important to note that, in these three patients, there were no 
hemodynamic changes associated with hematologic changes. Similar immunological 
activation has been recently reported with patients receiving hemodialysis or 
cardiopulmonary bypass. This is an area in need of further investigation. 
Hemodynamic and Oxygen Transport Effects: 
Fluosol has been shown to significantly increase the Ca02 (0.7 ml/dl at Fct 
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of 5% and a Pa02 of 363 torr) in these patients. This increase in Ca02 produced 
improved hemodynamics and oxygen utilization; V02 increased with a decrease in 
C.!. In all cases the patients were objectively improved and consequently had an 
increased margin of safety for their surgical procedure. From the data showing 
the haemodynamic and oxygen content changes after Fluosol we have demonstrated 
that Fluosol is carrying the expected oxygen and that this amount of oxygen is 
clinically significant. The clincial significance in these patients increased 
with decreasing hemoglobin. It must be pointed out that none of these patients 
had significant cardiac disease and they were able to compensate for the severe 
anemia without cardiac decompensation. Obviously a patient with severe cardiac 
disease would not tolerate this severe anemia and might clinically benefit from 
Fluosol at even higher hemoglobin values. 
Calculated Ca02: 
Table XIV presents measured and calculated oxygen content values that allow a 
reasonable estimate of the Ca02 (with Fluosol) to be determined if the Hct, Fct, 
and Pa02 are known. 
In conclusion, it appears that there is a future for PFC emulsions as a 
treatment for inadequate oxygen 
indication for Fluosol therapy. 
transport. This work demonstrates one possible 
In the future, other uses may prove valuable, 
i.e., carbon monoxide poisoning, acute myocardial infarction, cerebral vasospasm, 
or other acute microvascular oxygen transporting defects. However, the 
development of artificial red cell substitutes must proceed with cautious 
optimism until the acute and chronic side effects are more fully understood. 
Significant Hemodynamic Reaction to the Fluosol test dose: 
The fourth patient entering the study had a severe symptomatic and haemo-
dynamic reaction to a test dose of Fluosol (Figure 11). 
Approximately two minutes after receiving !,; cc of Fluosol, this 51 year old 
male with no known allergies complained of shortness of breath and a diffuse 
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SIGNIFICANT HEMODYNAMIC REACTION TO 
A 1/2 CC TEST DOSE OF FLUOSOL DA 20% 
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Fig 11 The above four-part figure presents graphically the time 
course of one patients significant hemodynamic reaction to a 
~ cc test dose of Fluosol. Note the normotensive bradycardia 
(upper) commenced with nearly compensating changes in CI and 
SVRI (second from top). The pulmonary pressures increased 
even more severely (second from bottom). The precipitous drop 
in Pa02 could not be entirely attributed to the reaction 
because the anxious patient removed his non-breathing oxygen 
mask, although the larger drop in Ptc02 relative to Pa02 does 
imply tissue hypoxia and is consistent ~<ith the increased 
SVRI. 
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pressure pain of the chest. The patient became agitated but remained alert and 
cooperative. These symptoms were coincident with the following hemodynamic 
changes: normotensive bradycardia to a rate of 30 beats per minute, a 35% drop 
in cardiac output, a 
increase in pulmonary 
50% increase in systemic vascular resistance, and a 100% 
artery systolic and diastolic pressure. The Pa02 dropped, 
but this was due to the patient removing his oxygen mask. The Ptc02 dropped in 
greater proportion, implying decreased peripheral oxygen delivery. The changes 
and associated symptoms gradually resolved over the next three minutes without 
treatment. The study was terminated and serial EKG's, cardiac enzymes and Pa02 
values revealed no resultant cardiac or pulmonary damage. 
After this vasoconstrictive reaction, we consulted with Dr. Greg Verce11otti 
of the University of Minnesota, Hematology Department, who had been conducting 
research of the potential cause of a similar reaction seen in the first U.S. 
patient administered Fluosol at the University of l~innesota. Dr. Vercellotti had 
noted similar reactions in rabbits~ with acute transient decreases in white blood 
cell and platelet counts during the reaction. He explained the reaction as an 
activation of complement through the alternative pathway which initiates a 
self-limiting cascade. The activation produces fragments which cause the WBC 1 s 
to be surface active and marginate to the blood vessel walls, predominately in 
the pulmonary bed. This produces a transient five minute leukopenia. Of major 
importance was the finding that high-dose glucocorticoids inhibit granulocyte 
sequestration and affregation, at just the concentrations which appeared to 
obviate the pulmonary complications seen in the first patient. Utilizing this 
information, complete blood counts were taken before the test dose, and five and 
ten minutes after the test dose in subsequent patients. 
Mild reaction to the Fluosol test dose: 
The fifth patient entering the protocol also had a reaction to the test dose, 
but of a much milder type. The patient complained of a vague abdominal/chest 
pressure sensation which lasted less than one minute. The only objective changes 
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HEMODYNAMICS AND WBC DURING 
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Fig 12 The above three part figure graphically presents the time 
course of some of the monitored parameters of a patient who 
had a very mild symptomatic reaction to the test dose of 
Fluosol. There were no significant changes in HR and MAF 
upper section) or CI and SVRI {lower section). The PAS did 
not rise transiently and also corresponded to a dramatic drop 
in W8C (middle section). This was the first patient in whom 
WBC 1 s were taken before and after the test dose. 
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were an increase in pulmonary artery systolic pressure (PAS),and a WBC drop from 
10,000 to 3.600 and back to 10,000 at ten minutes. The heart rate, MAP, cardiac 
output and SYR all rernai ned unchanged (Figure 12). 
Several clinical and experimental observations suggested that these phenomena 
could be prevented in patients by pretreatment with corticosteriods or by 
combinations of drugs including corticosteriods (see below). The patient 
therefore consented to, and received, a 2.0 gram bolus (30 mg/kg) of Solu-Medrol 
IV and 50 mg of Benadryl IM, and was rechallenged with 0.25 ml Fluosol. The PAS 
again rose. Another 0.25 ml of Fluosol was administerd five minutes later, and 
the PAS increased further, with the patient reporting a very mild chest sensation 
but no shortness of breath or pain. Concomitant serial WBC counts taken over the 
entire course of Fl uosol admi ni strati on demonstrated a sharp transient and 
intennittent drop paralleling the rise in PAS, with a return to nonnal PAS 
pressure, comensurate with the recovery to a normal WBC count. Solu-Medrol 
blunted the extent of the phenomenon. Two additional test doses were 
administered during the next 1 to 1~ hours. The same response was observed 
physiologically, even though the patient no longer had any symptoms and did not 
complain of any discomfort. No further attempts were made to infuse Fluosol. 
WBC changes after a test dose: 
Neither of the last two patients entered into the study had symptomatic and 
hemodynamic reactions to the test dose but both had decreases in WBC 1 S to a mean 
of 35% of baseline at five minutes, and all WBC's returned to baseline at 10 
minutes. Platelet counts were taken in one patient and they followed the sro~e 
pattern (Figure 13). 
The clinical experience to date have indicated that adverse reactions are 
therapeutically manangeable. The possiblity that they may be predictable by in 
vitro testing of the patient's plasma is currently under investigation. It is of 
interest to note that these reactions have been far more common in the American 
experience than the Japanese. There are however, dietary differences which may 
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result in differences in blood cell functions between the Japanese and the 
Americans. 
WBC 
TRANSIENT HEMATOLOGIC CHANGES 
WITH A 1/2 CC TEST DOSE OF 
FLUOSOL DA 20% 
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10000 
sooo 
0 
400 
3 patients, 
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Platelet 
Count x 103 
Fig 13 
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without symptoms 
300 
0 5 10 minutes 15 
Time 
The above figures present the time trend of WBC (upper 
section) and platelet count (lower section) before and after 
the~ cc Fluosol test dose. These data were obtained from the 
last three patients entering the study, none of which had 
significant hanodynamic changes after the test dose. 
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CHAPTER VI 
DISCUSSION 
Surgery and anaesthesia can be efficiently and successfully performed in 
patients in whom homologous blood transfusions are either not available, or 
when the patient refuses to accept such a therapeutic modality due to religious 
objections. In order to embark on such unchartered grounds one must first 
assume the patient with a haemoglobin level far below 10 grams can indeed be 
operated on without serious complications. 
By using lactated ringer solutions and/or starch preparations one can 
compensate for the lost volume, but not for the loss in oxygen carrying 
capabilities. Volume replacement can only improve the condition of an anemic, 
volume depleted patient to a certain extent, at which time, oxygen carrying 
fluids together with high oxygen tension must be instituted if the patient is 
to survive. Fluorocarbons with their considerably smaller particle size than a 
red blood cell, coupled with their extremely high affinity for oxygen, (which 
is dissolved in the solution rather than chemically bound as it is to 
hemoglobin), have been shown to be effective in performing this task. 
In our laboratory and clinical studies Fluosol DA-20% has so far proved an 
excellent material with minimal side effects, which has been responsible for 
saving lives in anemic 
treatment of myocardial 
In addition, it is 
patients as well as opening new horizons in the 
infarctions, cerebral vascular accidents, and shock. 
proving to be a useful adjunct in the areas of 
reimplantation of severed extremities and of organ transplantations. 
In clinical trials in the United States we have employed Fluosol infusions 
in a total of 17 patients whose haemoglobin concentrations varied from 1,6 to 
7,2 gm per 100 ml. All patients received a test dose of 0.5 ml of Fluosol 
intravenously, preceeded by cortisone treatment. In all cases a short tenn 
leucopenia was observed which usually returned to normal after a few minutes. 
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In one case we observed bradycardia and pulmonary hypertension which resolved 
spontaneously. No complications other than these have been observed. Though 
reports of allergic reactions have been reported from Italy, no adverse 
reactions have been notified in reports from Japan on the use of Fluosol. 
It is almost impossible to compare the results obtained in our series with 
those of others because, in all other studies fluosol was used an an adjunct to 
blood whereas in this series no blood was used and fluosol was used as a 
substitute for blood. 
The surgical approach to a patient without blood transfusions as a 
foundation for intraoperative loss must start by reorienting our thinking 
toward minimising blood loss in the operating theatre. This can be 
accompli shed successfully by employing hypotensive anesthesia, 1 ocal i sed 
hypothermia and the extensive use of the electrosurgical knife or the laser 
apparatus. The shed blood is not discarded but rather collected intra-
operatively, 
banked blood. 
washed, and 
It must 
reinfused immediately, thus eliminating the need for 
be viewed as axiomatic that the best blood one can 
infuse into a patient is his own and that the best way to eliminate the 
necessity for homologous blood transfusions is to minimise, if not totally 
eliminate, 
determining 
and the 
loss during surgery. The operating time is extremely important in 
the incidence of mortality and morbidity of the patient in general 
anemic patient specifically. To that end, techniques aimed at 
shortening operative time are employed in our daily practice and a continuous 
effort is directed towards the development of new and expeditious techniques. 
The surgical techniques (which are discussed in Chapter II) include 
oesophageal stapling for the treatment of bleeding of oesophageal varices in 
the cirrhotic patient and internal iliac artery ligation for the treatment of 
uncontrollable bleeding of pelvic origin. The results that have been obtained 
in large numbers of patients are comparable to those obtained by other 
investigators using shunting procedures or massive blood transfusions. 
To stimulate red cell production in patients whose bone marrow is stressed 
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beyond normal requirements of replacing a normal daily turnover of red blood 
cells, we have successfully employed, in 730 patients, the use of total dose 
iron dextran. The dose may be calculated using the formula: total dose of iron 
to be administered .3 x weight in pounds of the patient x the deficit in 
haemoglobin. This therapy is combined with the administration of folic acid, 
vitamin 812, and anabolic steroid preparations. 
Anaesthetic techniques were modified so as to be able to successfully 
anesthetise the anemic patient with minimal side effects and better utilization 
of oxygen distribution while maintaining an adequate blood pressure for 
purposes of vital organ perfusions. We have attempted to minimize the use of 
inhalation anaesthesia and, whenever possible, employ regional block for pain 
control. When this approach was not possible, ketamine, diazepam, muscle 
relaxants, 
employed. 
high oxygen tension and minimum amounts of isofluorane were 
Consultations between 
directly 
the anaesthesiologist and surgeon 
responsible for tailoring the appropriate preoperatively, have been 
anaesthetic and surgical approach to the specific patient and thus decreasing 
the overall mortality and morbidity. 
Our experience with 5000 major surgical procedures in Jehovah 1 S Witnesses 1 
has demonstrated that anaesthesia and surgery can be carried out on patients 
with minimal reliance on the blood bank for intraoperative fluid replacement. 
It must therefore 
patients (who can 
be assumed from this vast clinical experience obtained from 
be viewed as a control group when compared to the general 
patient population in whom homologous transfusion are liberally employed), that 
perhaps clinicians tend to overtransfuse bank blood because it is readily 
available and 
age of ever 
not necessarily because the patient requires it. In the day and 
decreasing blood supply, which causes periodic shortages and 
necessitates cancellations of elective surgery, when absolute screening tests 
for hepatitis, and acquired idiopathic immune deficiency syndrome are still not 
available, we must learn from the data obtained from this control group and 
employ the lessons learnt to the benefit of all. We must deduce that blood 
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transfusions should only be given to patients who show the clinical 
manifestations of decreased oxygen carrying capacity and not necessarily to 
people with low hemoglobin concentrations. This philosophy will save 
resources, money and, hopefully, many 1 ives. 
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CHAPTER VII 
SUMMARY 
Chapter I -The aims of the study are explained in relation to the need to reduce 
reliance on homologous blood transfusions. 
Chapter II f~ajor surgery in Jehovah's Witnesses has been accomplished with 
mortality and morbidity figures that are comparable to those employing blood 
transfusions. We have employed in our approach the use of hypotensive 
anaesthesia, autotransfusion, localised hypothennia, the extensive use of the 
electrocautery and laser as well as modified surgical instrumentation in the 
drive to reduce operating and anaesthetic times. To aid in replacing lost red 
blood cell mass we have employed total dose intravenous iron dextran. Fluosol 
DA-20% was employed in patients having need of greater oxygen carrying capacity. 
Two specific approaches to special hemorrhagic problems which were frequently 
encountered (oesophageal varices, and pelvic bleeding} and their results are 
discussed. 
Chapter III - A discussion is presented, of the specific problems with which the 
anaesthesiologist is confronted when 
homologous blood transfusion is not 
presented with an anemic patient in whom 
possible. The technique to solve this 
dilemma is illustrated employing regional block as well as intravenous ketamine, 
diazepam, and muscle relaxant. Anaesthetic problems faced by the anaesthetist in 
dealing with the anemic patient have been successfully overcome. 
Chapter IV - Utilization of intraoperative autotransfusions to eliminate the need 
of transfusing banked blood in the various surgical subspecialties is discussed 
and the various apparatus to accomplish this modality of autologous blood 
replacement are discussed including the pros and cons of each such mechanical 
device. 
Chapter V- Historical background of perfluorochemicals as well as the laboratory 
experimentation prior to clinical use as discussed in the literature, as well as 
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our early clinical results with this oxygen carrying media in Jehovah Witness 
patients is outlined. Our clinical experience using fluosol DA-20% has shown it 
to be extremely effective in changing the ischaemic changes which were manifested 
by the anemic patient. A specific case of a patient successfully operated at a 
haemoglobin of 1.6 is discussed in detail to illustrate this point. Additional 
laboratory research performed at E.U.R. with myocardial ischaemia induced in pigs 
is specifically noted. It has been proven that through dilution with fluosol 
DA-20% the myocardial zone could be reduced. A case report of a patient with the 
lowest haemoglobin yet recorded receiving fluosol is analysed. 
In summary we can conclude as our introductory chapter has postulated that 
major surgery and anaesthesia has been safely conducted in 5,000 patients without 
the use of homologous blood transfusions. Fluosol can be used effectively as a 
blood substitute in anemic patients and could possibly also play a role in the 
prevention of ischemic changes of organs. 
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SAMENVATTING 
In de introductie van de thesis wordt naar voren gebracht, dat het doe1 van 
dit onderzoek is homologe bloedtransfusies bij operaties te vennijden. Dit 
wordt bereikt door bloedingen tijdens de operatie met speciale technieken te 
beperken en eventuee1 optredend bl oedverl i es met autotransfusi e of 
bloedvervangende middelen aan te vullen. 
In hoofdstuk II van deze thesis wordt aangegeven, dat chirurgie en 
anaesthesie veilig kunnen worden uitgevoerd bij pati€nten zonder het gebruik 
van homologe bloedtransfusies. Dit werd aangetoond met 5500 operaties bij 
Jehova's getuigen. Chirurgische ingrepen bij Jehova's getuigen gaan gepaard 
met een hogere mortaliteit en morbiditeit dan bij de pati€nten-groep, waarbij 
het uitvoeren van bloedtransfusies moge1ijk is. Uiteraard komen in de groep 
van Jehova 1 S getuigen geen complicaties van b1oedtransfusies voor. In deze 
groep pati§nten werd gebruik gemaakt van hypotensie, autotransfusie, locale 
hypothermi e, uitgbrei d gebrui k 
instrumentarium, waarbij de 
van diathermie, laser en aangepast chirurgisch 
operatietijd en de anaesthesietijd werden 
verminderd. Het bloedverlies werd aangevuld met intraveneuze toediening van 
Dextran. Bij pati§nten bij wie de zuurstoftransport-capaciteit moest worden 
vergroot werd Fluosol-DA 20% gebruikt. 
In hoofdstuk II worden verder twee specia1e operatietechnieken beschreven 
voor speciale hemorrnagische prob1emen, die bij bloedende oesofagusvarices en 
bloedingen in het kleine bekken optreden. 
In hoofdstuk Ill worden de speciale problemen besproken waarmee de 
anaesthesist te maken krijgt bij anaemische patii2nten, bij wie een homologe 
autotransfusie niet mogelijk is. Speciale technieken, zoals regionale 
anaesthesie, inductie van hypotensie, en het gebruik van Ketamine/Diazepam 
samen met een spierrelaxans worden bij deze patienten aangegeven. 
Het gebruik van autotransfusie bij verschi11ende chirurgische ingrepen, om 
daarmee de noodzaak van bloedtransfusies te voorkomen, wordt in hoofdstuk IV 
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beschreven. De verschillende hiervoor benodigde technische voorzieningen 
worden besproken met al hun voor- en nadelen. Verder wordt in dit hoofdstuk 
het resultaat vermeld van het gebruik van intraveneuze ijzertoediening. 
In hoofdstuk V wordt het nieuwe bloedvervangende middel fluorocarbon 
besproken. Allereerst wordt de historische achtergrond van de ontwikkeling van 
perfluorocarbonen in het dierexperimentele en klinische gebruik, zeals in de 
literatuur beschreven, uiteengezet. Eigen klinische resultaten met het gebruik 
van dit bloedvervangende zuurstofdragende middel bij Jehova's getuigen worden 
beschreven. Fluosol-DA 20% bleek buitengewoon effectief in anaemische 
patienten. Een 1 Case report 1 wordt gegeven van een patient die met succes 
werd geopereerd bij een Hb van 1,6 gr. %. Resultaten van experimenten met 
fluorocarbon bij varkens worden weergegeven. Het effect van Fluosol-DA 20% 
werd getest in een experimenteel model waarbij ischemie van het hart werd 
geinduceerd bij varkens. Aangetoond werd, dat haemodilutie met Fluosol-DA 20% 
het ischaemische gebied in het myocard kon verkleinen. 
Geconcludeerd kan worden, dat chirurgische ingrepen uitgevoerd kunnen 
worden zonder het gebruik van homologe bloedtransfusies. Fluosol kan effectief 
worden gebruikt als bloedvervangend middel bij anaemische patienten en zou 
mogelijk oak bij de preventie van ischaemische veranderingen van organen een 
rol kunnen spelen. 
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